

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

The Alberta Health Services shall provide cancer drugs specified in the Outpatient Cancer Drug Benefit Program, at no charge, to eligible residents for the treatment of cancer as outlined in Ministerial Order # 10/2009

DEFINITIONS

“Eligible resident” means a person who:

1. holds a valid certificate of registration under the *Health Insurance Premiums Act*,
2. is registered in the Cancer Registry with a disease classified in the *International Classification of Diseases for Oncology*, and
3. requires cancer drugs to treat cancer.

“Cancer Pharmacy” means the pharmacy at the Cross Cancer Institute and the Tom Baker Cancer Centre, and other pharmacies operated by or for cancer centre as outlined in Ministerial Order #10/2009

Subject to this Ministerial Order, Cancer Drugs may be:

1. administered directly to in-patients or out-patients of Cancer Centres, or
2. sent to:
 - i) other health care providers; or
 - ii) a pharmacy that is owned or operated by or for Alberta Health Services, for administration or provision directly to the patient.

GROUP 1 DRUG LIST

Cancer Drugs in group 1 of the Schedule may be dispensed by a Cancer Pharmacy pursuant to a prescription written by a person who is authorized by the Alberta Health Services to prescribe Cancer Drugs and who is a physician, a regulated member under the *Health Professions Act* authorized to prescribe drugs, or a person authorized to prescribe drugs pursuant to another enactment.

GROUP 2 DRUG LIST

Cancer Drugs in group 2 of the Schedule may be dispensed by a Cancer Pharmacy only if the initial prescription is written by a Cancer Centre Medical Staff member, but a subsequent prescription for the same patient may be written by a person authorized by Alberta Health Services to prescribe Cancer Drugs and who is a physician, a regulated member under the *Health Professions Act* authorized to prescribe drugs, or a person authorized to prescribe drugs pursuant to another enactment. The following physicians from the CCI and TBCC are automatically named on all Group 2 drugs contained on the following pages:

(CCI: Dr. N. Basappa, Dr. S. Basi, Dr. A. Belch, Dr. C. Butts, Dr. M. Chu, Dr. Q. Chu, Dr. N. Chua, Dr. J. Easaw, Dr. A.L.A. Fields, Dr. A. Fontaine, Dr. M. Ho, Dr. A. Joy, Dr. K. King, Dr. M. Kolinsky, Dr. S. Koski, Dr. J. Mackey, Dr. J. Meza-Junco, Dr. K. Mulder, Dr. S. North, Dr. J. Price Hiller, Dr. L. Saini, Dr. R. Sangha, Dr. M. Sawyer, Dr. A. Scarfe, Dr. M. Smylie, Dr. J. Spratlin, Dr. M. Taparia, Dr. K. Tonkin, Dr. A.R. Turner, Dr. C. Venner, Dr. P. Venner, Dr. J. Walker);

(TBCC: Dr. N. Alimohamed, Dr. G. Bebb, Dr. V. Bramwell, Dr. C. Card, Dr. T. Cheng, Dr. S. Dowden, Dr. J. Henning, Dr. D. Hao, Dr. D. Heng, Dr. V. Krause, Dr. R. Lee-Ying, Dr. S. Lupichuk, Dr. H. McArthur, Dr. J. Monzon, Dr. D. Morris, Dr. N. Nixon, Dr. A. Paterson, Dr. G. Roldan Ugoiti, Dr. D. Ruether, Dr. D. Stewart, Dr. V. Tam, Dr. P. Tang, Dr. R. Tsang, Dr. S. Verma, Dr. M. Webster, Dr. V. Zepeda)

GROUP 3 DRUG LIST

Cancer Drugs in group 3 of the Schedule may be dispensed by a Cancer Pharmacy if

(a) the Cancer Drugs are part of a research or clinical drug trial approved by Alberta Health Services and the prescription is written by the principal investigator or co-investigator in charge of the trial, or

(b) the Cancer Drugs are approved for special access by Health Canada and a prescription is written by a Cancer Centre Medical Staff member designated as eligible by Albert Health Services to prescribe special access Cancer Drugs.

Reference: Ministerial Order #10/2009.

ADMINISTRATION CLASSIFICATION

| CLASSIFICATION DESCRIPTION | DELIVERY SITE | STANDARDS |
|--|--|--|
| <p>Basic</p> <ul style="list-style-type: none"> • Protocols including drugs (single agent or in combination) that can be administered with basic knowledge of chemotherapy. • Protocols including vesicants or drugs that are considered highly toxic where significant assessment and evaluation are required. • Protocols for basic clinical trials may be included on a case by case decision. | <ul style="list-style-type: none"> • Tertiary cancer centre • Regional cancer centre • Community cancer centre | <ul style="list-style-type: none"> • Medical, nursing and pharmacy staff shall have successfully completed the established Cancer chemotherapy training programs. • Nurses will be certified in advanced chemotherapy and central venous catheters. • Pharmacy staff shall be certified in chemotherapy preparation and handling. |
| <p>Advanced</p> <ul style="list-style-type: none"> • Protocols including complex clinical trials, investigational drugs, new drugs, drugs requiring complex delivery devices (ex. electronic continuous infusion pumps) • Advanced chemotherapy in Community cancer centres, at this time, refers to medications only. It does not include advanced administration methods (i.e. electronic pumps) or complex clinical trials. | <ul style="list-style-type: none"> • Tertiary cancer centre • Regional cancer centre Designated Community cancer centres: Barrhead, Bonnyville, Camrose, Canmore, Drayton Valley, Drumheller, Fort McMurray, High River, Hinton, Lloydminster | <ul style="list-style-type: none"> • As for Basic Classification. • Physicians supervising the complex clinical trials and investigational drug trials must have ready access to diagnostic procedures and data management. • Medical, nursing, and pharmacy staff shall have the knowledge and skill to manage complex delivery devices. |
| n/a | <ul style="list-style-type: none"> • Any health care setting • For oral and SC medications • Patient may self-administer | <ul style="list-style-type: none"> • No special training for health care professional required to administer. |

“Cancer Centre” means the following centres:

- Alberta Children’s Hospital (Calgary)
- Peter Lougheed Centre (Calgary)
- Stollery Children’s Hospital (Edmonton)
- University of Alberta Hospital (Edmonton)
- Tom Baker Cancer Centre, and the following regional and community centres:
 - Jack Ady Cancer Centre (Lethbridge)
 - Margery E. Yuill Cancer Centre (Medicine Hat)
 - Drumheller Community Cancer Centre
 - High River Community Cancer Centre
 - Bow Valley Community Cancer Centre
- Cross Cancer Institute, and the following regional and community centres:
 - Central Alberta Cancer Centre (Red Deer)
 - Grande Prairie Cancer Centre
 - Barrhead Community Cancer Centre
 - Bonnyville Community Cancer Centre
 - Camrose Community Cancer Centre
 - Fort McMurray Community Cancer Centre
 - Hinton Community Cancer Centre
 - Peace River Community Cancer Centre
 - Lloydminster Community Cancer Centre
 - Drayton Valley Community Cancer Centre

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|-------------|-------|-------------|---|--|-------------------------------|
| ABIRATERONE | 2 | oral | <p><u>Metastatic Castrate Resistant Prostate Cancer (mCRPC)</u></p> <ul style="list-style-type: none"> For asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) patients after failure of androgen deprivation therapy (ADT) and who have not received prior chemotherapy or if patients are unable to tolerate ongoing enzalutamide in this pre-docetaxel setting. Prescribing limited to written authorization by named physicians: <p>CCI Dr. N. Basappa, Dr. B. Danielson, Dr. M. Kolinsky, Dr. A. Murtha, Dr. S. North, Dr. P. Venner</p> <p>TBCC Dr. N. Alimohamed, Dr. T. Cheng, Dr. D. Heng, Dr. S. Husain, Dr. R. Lee-Ying, Dr. N. Nixon, Dr. A. Pabani, Dr. D. Ruether, Dr. V. Tam</p> <p>Grande Prairie Dr. M. Moreau</p> <p>Lethbridge Dr. M. Brigden, Dr. A. Imbulgoda, Dr. N. Lavens</p> <p>Medicine Hat Dr. S. Raissouni</p> <p>Red Deer Dr. N. Basappa, Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. C. Tarukandirwa, Dr. J. Walker</p> <p>Alberta Urology Institute Dr. M. Chetner, Dr. A. Fairey</p> <p>Southern AB Urology Institute Dr. B. Donnelly, Dr. G. Grotto</p> <p>As recommended by the genitourinary tumour program or outlined under group 2 drugs on first page.</p> | <p>May/14 Dec/15</p> <p>Feb/12</p> | |
| | | | <p><u>Metastatic Castrate Resistant Prostate Cancer (mCRPC)</u></p> <ul style="list-style-type: none"> For treatment of metastatic, castration-resistant prostate cancer, who have previously received docetaxel therapy or if patients are unable to tolerate ongoing enzalutamide in this post docetaxel setting. Not to be used after progression on enzalutamide in the post-docetaxel setting (could have progressed on enzalutamide in pre-docetaxel setting. Not to be used after progression on Abiraterone in the pre-docetaxel setting. Prescribing limited to written authorization by named physicians: <p>CCI Dr. N. Basappa, Dr. M. Kolinsky, Dr. S. North, Dr. P. Venner</p> <p>TBCC Dr. N. Alimohamed, Dr. T. Cheng, Dr. D. Heng, Dr. R. Lee-Ying, Dr. N. Nixon, Dr. A. Pabani, Dr. D. Ruether, Dr. V. Tam</p> <p>Grande Prairie Dr. M. Moreau</p> <p>Lethbridge Dr. M. Brigden, Dr. A. Imbulgoda, Dr. N. Lavens</p> <p>Medicine Hat Dr. S. Raissouni</p> <p>Red Deer Dr. N. Basappa, Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. C. Tarukandirwa, Dr. J. Walker</p> <p>As recommended by the genitourinary tumour program or outlined under group 2 drugs on first page.</p> | <p>Dec/13 May/14 Dec/15</p> | |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|---|-------|-------------|---|---------------|-------------------------------|
| AFATINIB | 2 | oral | <p>Lung</p> <ul style="list-style-type: none">• First line treatment of patients with EGFR mutation positive advanced or metastatic adenocarcinoma of the lung and with an ECOG performance status of 0 or 1 or if patients are unable to tolerate gefitinib. Not to be used after progression on gefitinib• Prescribing limited to written authorization by named physicians: <p>CCI Dr. D. Au, Dr. N. Basappa, Dr. C. Butts, Dr. Q. Chu, Dr. A. Joy, Dr. R. Sangha, Dr. M. Sawyer, Dr. M. Smylie</p> <p>TBCC Dr. G. Bebb, Dr. C. Card, Dr. D. Hao, Dr. V. Krause, Dr. D. Morris, Dr. N. Nixon, Dr. A. Pabani, Dr. D. Ruether, Dr. V. Tam, Dr. R. Tsang</p> <p>Grande Prairie Dr. M. Moreau</p> <p>Lethbridge Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. S. Raissouni</p> <p>Red Deer Dr. N. Basappa, Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. C. Tarukandirwa, Dr. J. Walker</p> <p>As recommended by the lung tumour program or outlined under group 2 drugs on first page.</p> | Sept/14 | n/a |
| ALDESLEUKIN (INTERLEUKIN-2, IL-2) intralesionally | 2 | injectable | <p>Melanoma</p> <ul style="list-style-type: none">• For the treatment of unresectable in-transit metastatic melanoma (ie patients with rapidly developing in-transit metastases after surgery or patients who present with multiple in-transit metastases unsuitable for surgical resection)• Prescribing limited to written authorization by named physicians: <p>CCI Dr. K. Dabbs, Dr. D. Olson, Dr. T. Salopek, Dr. M. Smylie, Dr. J. Walker</p> <p>TBCC Dr. T. Cheng, Dr. D. Mew, Dr. J.G. McKinnon, Dr. J. Monzon, Dr. M.L. Quan, Dr. C. Temple-Oberle</p> <p>As recommended by the cutaneous tumour group program or outlined under group 2 drugs on first page.</p> | Dec/15 | |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|-------------|-------|-------------|---|---|-------------------------------|
| ALEMTUZUMAB | 2 | injectable | <p>Hematology</p> <ul style="list-style-type: none"> • Subcutaneous plus fludarabine for previously treated CLL • Prescribing limited to written authorization by named physicians: <p>CCI</p> <p>Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. S. Takach Lapner, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC</p> <p>Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. M. Wong, Dr. V. Zepeda</p> <p>Grande Prairie</p> <p>Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau, Dr. G. Nikoleychuk</p> <p>Lethbridge</p> <p>Dr. S. Benke, Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat</p> <p>Dr. J. Foley, Dr. S. Raissouni</p> <p>Red Deer</p> <p>Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. K. Rudolph, Dr. C. Tarukandirwa</p> <p>As recommended by the hematology tumour program or outlined under group 2 drugs on first page.</p> | Apr/12 | basic - SC |
| ANAGRELIDE | 1 | capsules | | Mar/98 Apr/09 | n/a |
| ANASTROZOLE | 1 | tablets | | Apr/03 Nov/03 May/06 Mar/13 June/13 | n/a |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|------------------|-------|-------------|---|------------------|-------------------------------|
| ARSENIC TRIOXIDE | 2 | injectable | <p>Hematology</p> <ul style="list-style-type: none"> For patients with APL with t(15:17) translocation and/or PML/RAR-alpha gene expression. <ul style="list-style-type: none"> First line treatment in combination with all-trans retinoic acid (ATRA) for the induction of remission and/or consolidation in patients with low or intermediate risk acute Promyelocytic leukemia (APL) and with ATRA and chemotherapy for high risk APL. Second line treatment for induction of remission and consolidation in patients with APL who have relapsed after completion of first line therapy (including ATO based regimens) or who have disease refractory to non ATO based regimens Prescribing limited to written authorization by named physicians: <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. S. Takach Lapner, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. M. Wong, Dr. V. Zepeda</p> <p>Grande Prairie Dr. J. Hattingh, Dr. S. Marcotte. Dr. M. Moreau, Dr. G. Nikoleychuk</p> <p>Lethbridge Dr. S. Benke, Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. J. Foley, Dr. S. Raissouni</p> <p>Red Deer Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. K. Rudolph, Dr. C. Tarukandirwa</p> <p>As recommended by the hematology tumour program or outlined under group 2 drugs on first page</p> | May/14 Mar/15 | advanced |
| ASPARAGINASE | 1 | injectable | | | advanced |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|-------------|-------|-------------|---|------------------|---------------------------------|
| AXITINIB | 2 | | <p>Renal</p> <ul style="list-style-type: none"> As second-line treatment of patients with metastatic clear cell renal carcinoma who, based on the mutual assessment of the treating physician and the patient, are unable to tolerate ongoing use of an effective dose of everolimus or who have a contraindication to everolimus. Not to be used after progression on Nivolumab, may be considered if intolerant to Nivolumab. Prescribing limited to written authorization by named physicians: <p>CCI Dr. N. Basappa, Dr. M. Kolinsky, Dr. S. North, Dr. P. Venner</p> <p>TBCC Dr. N. Alimohamed, Dr. T. Cheng, Dr. D. Heng, Dr. R. Lee-Ying, Dr. N. Nixon, Dr. A. Pabani, Dr. D. Ruether, Dr. V. Tam</p> <p>Grande Prairie Dr. M. Moreau</p> <p>Lethbridge Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. S. Raissouni</p> <p>Red Deer Dr. N. Basappa, Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. C. Tarukandirwa, Dr. J. Walker</p> <p>As recommended by the genitourinary tumour program or outlined under group 2 drugs on first page.</p> | Mar/14 Apr/17 | |
| AZACITIDINE | 1 | injectable | | May/10 Jun/14 | basic |
| BCG | 1 | injectable | | Jan/91 Apr/09 | Bladder instillation - basic |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|--------------|-------|-------------|--|--|-------------------------------|
| BENDAMUSTINE | 2 | injectable | <p>Hematology</p> <ul style="list-style-type: none"> • As a single agent for the treatment of relapsed or refractory indolent B-cell lymphoma in patients who are refractory or intolerant to rituximab. • In combination with rituximab as first-line therapy in patients with indolent B-cell lymphoma or mantle cell lymphoma with an ECOG performance status of equal or less than 2. • In combination with rituximab for relapsed/refractory patients with indolent B-cell lymphoma or mantle cell lymphoma. • For the first line treatment of patients with chronic lymphocytic leukemia (Binet stage B or C and WHO performance status ≤ 2) who are not medically fit to tolerate fludarabine based regimens • Prescribing limited to written authorization by named physicians: <p>CCI</p> <p>Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. S. Takach Lapner, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC</p> <p>Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. M. Wong, Dr. V. Zepeda</p> <p>Grande Prairie</p> <p>Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau, Dr. G. Nikoleychuk</p> <p>Lethbridge</p> <p>Dr. S. Benke, Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat</p> <p>Dr. J. Foley, Dr. S. Raissouni</p> <p>Red Deer</p> <p>Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. K. Rudolph, Dr. C. Tarukandirwa</p> <p>As recommended by the hematology tumour program or outlined under group 2 drugs on first page.</p> | <p>Mar/14 Apr/17</p> <p>Mar/13 Apr/17</p> <p>Apr/17</p> <p>July/13</p> | <p>basic</p> |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|-------------|-------|-------------|---|-----------------------------|-------------------------------|
| BEVACIZUMAB | 2 | Injectable | <p>Colorectal</p> <ul style="list-style-type: none"> In combination with chemotherapy with one line of chemotherapy for the treatment of advanced colorectal cancer (indicated for any line of therapy provided bevacizumab naïve) Prescribing limited to written authorization by named physicians: <p>CCI Dr. N. Basappa, Dr. C. Butts, Dr. N. Chua, Dr. J. Easaw, Dr. A.L.A. Fields, Dr. A. Fontaine, Dr. M. Ho, Dr. K. King, Dr. S. Koski, Dr. K. Mulder, Dr. J. Price Hiller, Dr. M. Sawyer, Dr. A. Scarfe, Dr. J. Spratlin, Dr. J. Walker, Dr. C. Wong, Dr. X. Zhu</p> <p>TBCC Dr. G. Bebb, Dr. W. Blahey, Dr. T. Cheng, Dr. W. Cheung, Dr. S. Dowden, Dr. V. Krause, Dr. R. Lee-Ying, Dr. S. Lupichuk, Dr. J. Monzon, Dr. D. Morris, Dr. N. Nixon, Dr. S. Paterson, Dr. G. Roldan Urgoiti, Dr. D. Ruether, Dr. H. Samawi, Dr. D. Stewart, Dr. V. Tam, Dr. P. Tang, Dr. T. Thael, Dr. R. Tsang</p> <p>Grande Prairie Dr. M. Moreau</p> <p>Lethbridge Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. S. Raissouni</p> <p>Red Deer Dr. N. Basappa, Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. C. Tarukandirwa, Dr. J. Walker</p> <p>As recommended by the gastrointestinal tumour program or outlined under group 2 drugs on first page</p> | <p>Apr/09</p> <p>Mar/13</p> | <p>basic</p> |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|--------------|-------|-------------|--|------------------|--|
| BEVACIZUMAB | 2 | injectable | <p><u>Carcinoma of the Cervix:</u></p> <ul style="list-style-type: none"> In combination with chemotherapy <ul style="list-style-type: none"> For patients with metastatic (Stage IVB), persistent or recurrent carcinoma of the cervix of all histologic subtypes (except small cell) with good performance status. For retreatment of patients after a complete response with chemotherapy and bevacizumab and who have been off systemic therapy for a period of 6 months. Not to be used after progression occurring while on bevacizumab. | Dec/15 | |
| | | | <p><u>Epithelial, Ovarian, Primary Peritoneal and Fallopian Tube Cancer</u></p> <ul style="list-style-type: none"> In combination with carboplatin and a taxane in the front line treatment of patients with advanced stage "high risk for progression" epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer that has good performance status. (High risk for progression defined as Stage III with > 1 cm of residual disease, Stage III unresectable, or Stage IV). Dosing limited to 7.5 mg/kg and for a maximum of 17 cycles (in combination with chemotherapy for cycles 2 to 6 and as a single agent in maintenance therapy for up to 12 additional cycles). Prescribing limited to written authorization by names physicians: | Dec/15 | |
| | | | <p>CCI Dr. V. Capstick, Dr. M. Ho, Dr. S. Pin, Dr. J. Sabourin, Dr. A. Schepansky, Dr. H. Steed, Dr. K. Tonkin, Dr. T. Wells</p> <p>TBCC Dr. A. Cameron, Dr. P. Chu, Dr. P. Ghatage, Dr. S. Glaze, Dr. J. Nation, Dr. G. Nelson</p> <p>Grande Prairie Dr. M. Moreau, Dr. C. Strehlke</p> <p>Red Deer Dr. H. Karachiwala, Dr. C. Tarukandirwa</p> <p>Lethbridge Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. S. Raissouni</p> <p>As recommended by the gynecology tumour group program, or outlined under group 2 drugs on first page.</p> | Oct/16 | |
| BICALUTAMIDE | 1 | tablets | | May/97 Apr/09 | n/a |
| BLEOMYCIN | 1 | injectable | | | sc test dose, IV push, inf - basic |
| | 1 | pump | | | electronic continuous infusion pump - advanced |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|------------|-------|--------------------------------------|---|---|---|
| BORTEZOMIB | 2 | injectable IV or SC at 1 mg/mL | <p>Hematology</p> <ul style="list-style-type: none"> • Relapsed Multiple Myeloma • In the first line treatment of previously untreated Multiple Myeloma who are not candidates for autologous stem cell transplantation (HDT-ASCT) • Monotherapy or combination treatment for relapsed or refractory mantle cell lymphoma • As a component of induction therapy prior to and/or as a component of the high dose therapy for autologous stem cell transplantation (ASCT) for newly diagnosed patients with multiple myeloma who are eligible for ASCT • Post autologous stem cell transplantation (ASCT) for 4 cycles of consolidation in those patients who obtained only partial response or stable disease and for maintenance therapy for two years in those patients who have the del17p, t(4;14), or t(14;16). Concurrent use with lenalidomide maintenance is approved in these high risk patients. • Maintenance Bortezomib given every 2 weeks until progression (for up to 2 years) after induction chemotherapy for transplant ineligible multiple myeloma patients. • For the treatment of patients with AL amyloidosis arising from a clonal plasma cell dyscrasia with symptomatic organ involvement ineligible for autologous stem cell transplant. • Prescribing limited to written authorization by named physicians: <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. S. Takach Lapner, Dr. M. Taparia, Dr. A R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. M. Wong, Dr. V. Zepeda</p> <p>Grande Prairie Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau, Dr. G. Nikoleychuk</p> <p>Lethbridge Dr. S. Benke, Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. J. Foley, Dr. S. Raissouni</p> <p>Red Deer Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. K. Rudolph, Dr. C. Tarukandirwa</p> <p>As recommended by the hematology tumour program or outlined under group 2 drugs on first page.</p> | Aug/06 May/08 July/11 Oct/12 Jul/13 Jul/15 Jul/13 Sep/14 Mar/15 Jan/16 Aug/15 | basic IV or SC 1 mg/mL concentration |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|-----------|-------|-------------|--|---------------|-------------------------------|
| BOSUTINIB | 2 | oral | <p>Hematology</p> <ul style="list-style-type: none">• For the treatment of patients with chronic, accelerated, or blast phase Philadelphia chromosome positive (Ph+ve) chronic myelogenous leukemia (CML) who have resistance or intolerance to prior TKI therapy, and for whom subsequent treatment with imatinib, nilotinib and Dasatinib is not clinically appropriate.• Prescribing limited to written authorization by named physicians: <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. S. Takach Lapner, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. M. Wong, Dr. V. Zepeda</p> <p>Grande Prairie Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau, Dr. G. Nikoleychuk</p> <p>Lethbridge Dr. S. Benke, Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. J. Foley, Dr. S. Raissouni</p> <p>Red Deer Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. K. Rudolph, Dr. C. Tarukandirwa</p> <p>As recommended by the hematology tumour program or outlined under group 2 drugs on first page.</p> | Jan/16 | |

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|---------------------|-------|-------------|--|---------------|-------------------------------|
| BRENTUXIMAB VEDOTIN | 2 | injectable | <p>Hematology – Hodgkin’s Lymphoma</p> <ul style="list-style-type: none"> For patients with Hodgkin’s lymphoma who have relapsed disease following autologous stem cell transplant (ASCT) and who have an ECOG performance status of 0 or 1. For patients who weigh more than 100 kg doses are based on a weight of 100 kg. <p>Hematology – Systemic Anaplastic Large Cell Lymphoma</p> <ul style="list-style-type: none"> As monotherapy in patients with systemic anaplastic large cell lymphoma who have failed at least one prior multi-agent therapy and who have an ECOG performance status of 0 or 1. Prescribing limited to written authorization by named physicians: <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. S. Takach Lapner, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. M. Wong, Dr. V. Zepeda</p> <p>Grande Prairie Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau, Dr. G. Nikoleychuk</p> <p>Lethbridge Dr. S. Benke, Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. J. Foley, Dr. S. Raissouni</p> <p>Red Deer Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. K. Rudolph, Dr. C. Tarukandirwa</p> <p>As recommended by the hematology tumour program or outlined under group 2 drugs on first page.</p> | May/14 | advanced |
| BUSERELIN | 1 | injectable | <p>Prostate Cancer</p> <ul style="list-style-type: none"> Restricted to: <ul style="list-style-type: none"> Stage II (T2a-T2c): Neoadjuvant use pre RT (2 months pre and during RT). Neoadjuvant use pre radical prostatectomy (4 months pre). Stage III (T3a-T4b): Neoadjuvant use pre RT (2 months pre and during RT). Adjuvant use (3 years post RT). Stage IV (N1-N3) (M1-M1c): As monotherapy in medical castration. In total androgen blockade (medical castration and nonsteroidal antiandrogen). Guidelines for LHRH use in the above stated stages include: <ul style="list-style-type: none"> LHRH agonists are indicated for use in patients at risk of thromboembolic disease, strokes (CVA), myocardial infarction and also for consideration in patients with dyslipidemia, hypertension, diabetes mellitus or where a patient is considered intolerant to cyproterone acetate or megestrol acetate. | Jan/98 | n/a |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|--------------|-------|-----------------------|--|--|-------------------------------|
| BUSULFAN | 1 | tablets injectable | | Jul/16 | advanced IV |
| CABAZITAXEL | 2 | injectable | <p>Prostate Cancer</p> <ul style="list-style-type: none"> • Cabazitaxel plus prednisone for patients with castration resistant metastatic prostate cancer previously treated with a docetaxel containing regimen • Prescribing limited to written authorization by named physicians: <p>CCI Dr. N. Basappa, Dr. M. Kolinsky, Dr. S. North, Dr. P. Venner</p> <p>TBCC Dr. N. Alimohamed, Dr. T. Cheng, Dr. D. Heng, Dr. R. Lee-Ying, Dr. N. Nixon, Dr. A. Pabani, Dr. D. Ruether, Dr. V. Tam</p> <p>Grande Prairie Dr. M. Moreau</p> <p>Lethbridge Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. S. Raissouni</p> <p>Red Deer Dr. N. Basappa, Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. C. Tarukandirwa, Dr. J. Walker</p> <p>As recommended by the genitourinary tumour program or outlined under group 2 drugs on first page.</p> | Aug/12 May/14 | advanced |
| CAPECITABINE | 1 | oral | | Dec/98 Jul/02 Oct/03 Jan/04 Jun/14 | n/a |
| CARBOPLATIN | 1 | injectable | | May/85 | IV inf. - basic |
| | | | | May/16 | Intraperitoneal - advanced |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|------------|-------|-------------|--|---------------|-------------------------------|
| CARMUSTINE | 1 | injectable | <p>Hematology</p> <ul style="list-style-type: none">• Within BEAM regimen for patients undergoing high dose therapy and autologous stem cell transplantation• Prescribing limited to written authorization by named physicians: <p>CCI</p> <p>Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. S. Takach Lapner, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC</p> <p>Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. M. Wong, Dr. V. Zepeda</p> <p>Grande Prairie</p> <p>Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau, Dr. G. Nikoleychuk</p> <p>Lethbridge</p> <p>Dr. S. Benke, Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat</p> <p>Dr. J. Foley, Dr. S. Raissouni</p> <p>Red Deer</p> <p>Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. K. Rudolph, Dr. C. Tarukandirwa</p> <p>As recommended by the hematology tumour program or outlined under group 2 drugs on first page.</p> | Sept/14 | IV inf. - basic |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|--------------|-------|-------------|--|----------------------|---|
| CARMUSTINE | 2 | ointment | <p>Topical</p> <ul style="list-style-type: none"> • Carmustine topical for primary cutaneous lymphoma. • Prescribing limited to written authorization by named physicians: <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. S. Takach Lapner, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. M. Wong, Dr. V. Zepeda</p> <p>Grande Prairie Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau, Dr. G. Nikoleychuk</p> <p>Lethbridge Dr. S. Benke, Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. J. Foley, Dr. S. Raissouni</p> <p>Red Deer Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. K. Rudolph, Dr. C. Tarukandirwa</p> <p>As recommended by the hematology tumour program or outlined under group 2 drugs on first page.</p> | Apr/17 | n/a |
| CETUXIMAB | 2 | injectable | <p>Head and Neck Cancer</p> <ul style="list-style-type: none"> • Patient has locally or regionally advanced squamous cell carcinoma of the head and neck without distant metastases, and <ul style="list-style-type: none"> • have Karnofsky Performance score ≥ 90, and • cetuximab is used in combination with curative radical radiotherapy, and • recommended dosage is: Initially 400 mg/m², then 250 mg/m² weekly for six to seven weeks. • Prescribing limited to written authorization by named physicians: <p>CCI Dr. Q. Chu, Dr. N. Chua, Dr. S. Koski, Dr. J. Mackey</p> <p>TBCC Dr. D. Hao, Dr. M. Webster</p> <p>Lethbridge Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. S. Raissouni</p> <p>As recommended by the Head and Neck tumour group or outlined under group 2 drugs on first page.</p> | Oct/09 Oct/12 | advanced |
| CHLORAMBUCIL | 1 | tablets | | | n/a |
| CISPLATIN | 1 | injectable | | Mar/90 May/06 | IV inf. – basic Intraperitoneal - advanced |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|----------------------|-------|----------------------------|---|----------------------|--|
| CLADRIBINE | 1 | injectable subcutaneous | | Mar/96 Apr/09 | IV inf., sc - basic Electronic continuous infusion pump - advanced |
| CRIZOTINIB | 2 | oral | <p>Lung Cancer</p> <ul style="list-style-type: none"> • As a second line monotherapy for use in patients with anaplastic lymphoma kinase (ALK)-positive advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) in patients who have prior first line therapy. • As a monotherapy for use in patients with anaplastic lymphoma kinase (ALK)-positive advanced (not amendable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) • Prescribing limited to written authorization by named physicians: <p>CCI Dr. D. Au, Dr. N. Basappa, Dr. C. Butts, Dr. Q. Chu, Dr. A. Joy, Dr. R. Sangha, Dr. M. Sawyer, Dr. M. Smylie</p> <p>TBCC Dr. G. Bebb, Dr. C. Card, Dr. D. Hao, Dr. V. Krause, Dr. D. Morris, Dr. N. Nixon, Dr. A. Pabani, Dr. D. Ruether, Dr. V. Tam, Dr. R. Tsang</p> <p>Grande Prairie Dr. M. Moreau</p> <p>Lethbridge Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. S. Raissouni</p> <p>Red Deer Dr. N. Basappa, Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. C. Tarukandirwa, Dr. J. Walker</p> <p>As recommended by the lung tumour program or outlined under group 2 drugs on first page</p> | Oct/13 Dec/15 | basic |
| CYCLOPHOSPHAMIDE | 1 | injectable, tablets | | | IV push, inf. - basic |
| CYPROTERONE | 1 | tablets | | May/85 | n/a |
| CYTARABINE | 1 | injectable | | Mar/13 | IV push, IT, inf., SC – basic |
| CYTARABINE LIPOSOMAL | 1 | injectable | | Mar/01 Apr/09 | IT - advanced |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|--------------|-------|-------------|--|------------------|-------------------------------|
| DABRAFENIB | 2 | capsule | Melanoma <ul style="list-style-type: none">• Dabrafenib and/or trametinib for patients with BRAF V600 mutation positive, unresectable or metastatic melanoma in the first line setting and who have an ECOG performance status of 0 or 1. Treatment is until disease progression. If brain metastases are present, patient should be asymptomatic or have stable symptoms. Not to be used after progression on single-agent BRAF inhibitor or MEK inhibitor.• Prescribing limited to written authorization by named physicians: CCI Dr. M. Smylie, Dr. J. Walker TBCC Dr. T. Cheng, Dr. J. Monzon As recommended by the cutaneous tumour program or outlined under group 2 drugs on first page | Oct/16 Mar/15 | n/a |
| DACARBAZINE | 1 | injectable | | | IV inf. - basic |
| DACTINOMYCIN | 1 | injectable | | | IV push - basic |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|---------------|-------|---------------------|--|------------------|-------------------------------|
| DASATINIB | 2 | oral | <p>Hematology</p> <ul style="list-style-type: none"> • As first line treatment of Philadelphia Chromosome Positive CML in Chronic Phase (CML-CP) • For the treatment of adults with chronic, accelerated or blast phase chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy including imatinib mesylate. <p>Recommendations included the following:</p> <ul style="list-style-type: none"> • for adult patients with chronic phase CML with primary or acquired resistance to imatinib (600 mg/day) at doses of 100 mg per day or 70 mg two times daily • for adult patients with chronic phase CML who progress to accelerated phase on imatinib (600 mg/day). Dosing recommended: 140 mg per day • for adult patients with chronic phase CML who have blast crisis while on imatinib 600 mg/day. Dosing recommended: 140 mg per day • for adult patients with CML who have intolerance to imatinib or have experienced grade 3 or higher toxicities to imatinib • for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia whose disease is resistant to imatinib-containing chemotherapy (patient must have tried 600 mg/day) or have experienced grade 3 non-hematologic toxicity, or grade 4 hematologic toxicity persisting for more than 7 days to imatinib. <p>• Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. S. Takach Lapner, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. E. P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. M. Wong, Dr. V. Zepeda</p> <p>Grande Prairie Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau, Dr. G. Nikoleychuk</p> <p>Lethbridge Dr. S. Benke, Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. J. Foley, Dr. S. Raissouni</p> <p>Red Deer Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. K. Rudolph, Dr. C. Tarukandirwa</p> <p>As recommended by the hematology tumour program or outlined under group 2 drugs on first page.</p> | Oct/12 Oct/09 | n/a |
| DAUNORUBICIN | 1 | injectable | | | IV push, inf. - basic |
| DEXAMETHASONE | 1 | injectable, tablets | <ul style="list-style-type: none"> • Antiemetic use NOT covered. | | n/a |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|-----------------------|-------|-------------|--|--|--|
| DOCETAXEL | 1 | injectable | | Mar/01 Apr/03 Jun/14 | advanced - IV basic - intravesical use (bladder instillation) |
| DOXORUBICIN | 1 | injectable | | | IV push – basic Electronic continuous infusion pump - advanced |
| DOXORUBICIN LIPOSOMAL | 1 | injectable | | Feb/99 Mar/01 Jul/02 Feb/11 Jun/14 | advanced |
| ENZALUTAMIDE | 2 | oral | <p><u>Metastatic Castrate Resistant Prostate Cancer (mCRPC)</u></p> <ul style="list-style-type: none"> For the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy who have not received prior chemotherapy or if patients are unable to tolerate ongoing abiraterone in this pre-docetaxel setting. Prescribing limited to written authorization by named physicians: <p>CCI Dr. N. Basappa, Dr. B. Danielson, Dr. M. Kolinsky, Dr. A. Murtha, Dr. S. North, Dr. P. Venner</p> <p>TBCC Dr. N. Alimohamed, Dr. T. Cheng, Dr. D. Heng, Dr. S. Hussain, Dr. R Lee-Ying, Dr. N. Nixon, Dr. A. Pabani, Dr. D. Ruether, Dr. V. Tam</p> <p>Grande Prairie Dr. M. Moreau</p> <p>Lethbridge Dr. M. Brigden, Dr. A. Imbulgoda, Dr. N. Lavens</p> <p>Medicine Hat Dr. S. Raissouni</p> <p>Red Deer Dr. N. Basappa, Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. C. Tarukandirwa, Dr. J. Walker</p> <p>Alberta Urology Institute Dr. M. Chetner, Dr. A. Fairey</p> <p>Southern AB Urology Institute Dr. B. Donnelly, Dr. G. Grotto</p> <p>As recommended by the genitourinary tumour program or outlined under group 2 drugs on first page.</p> | Dec/13 Dec/15 | |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|--------------|-------|-------------|--|---------------------------------------|-------------------------------|
| ENZALUTAMIDE | 2 | oral | <p><u>Metastatic Castrate Resistant Prostate Cancer (mCRPC)</u></p> <ul style="list-style-type: none">• For the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have previously received docetaxel, or if patients are unable to tolerate ongoing abiraterone in this post-docetaxel setting. Not to be used after progression on abiraterone in the post-docetaxel setting (could have progressed on abiraterone in the pre-docetaxel setting). Not to be used after progression on enzalutamide in the pre-docetaxel setting. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. N. Basappa, Dr. M. Kolinsky, Dr. S. North, Dr. P. Venner</p> <p>TBCC Dr. N. Alimohamed, Dr. T. Cheng, Dr. D. Heng, Dr. R. Lee-Ying, Dr. N. Nixon, Dr. A. Pabani, Dr. D. Ruether, Dr. V. Tam</p> <p>Grande Prairie Dr. M. Moreau</p> <p>Lethbridge Dr. M. Brigden, Dr. A. Imbulgoda, Dr. N. Lavens</p> <p>Medicine Hat Dr. S. Raissouni</p> <p>Red Deer Dr. N. Basappa, Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. C. Tarukandirwa, Dr. J. Walker</p> <p>As recommended by the genitourinary tumour program or outlined under group 2 drugs on first page.</p> | Dec/15 | |
| EPIRUBICIN | 1 | injectable | | Mar/01 Jul/02 Sept/04 Jun/11 | IV push - basic |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|-----------|-------|-------------|--|--|-------------------------------|
| ERIBULIN | 2 | injectable | <p>Breast Cancer</p> <ul style="list-style-type: none"> For the treatment of patients with metastatic or incurable locally advanced breast cancer who have previous treatment with a taxane and an anthracycline, who have had at least two chemotherapy regimens for metastatic or locally recurrent disease and who have progressed after their last therapy. Patients must have good performance status (ECOG≤2). Prescribing limited to written authorization by named physicians: <p>CCI Dr. D. Au, Dr. S. Basi, Dr. M. Ho, Dr. A. Joy, Dr. K. King, Dr. J. Mackey, Dr. J. Meza-Junco, Dr. J. Price Hiller, Dr. A. Scarfe, Dr. M. Smylie, Dr. K. Tonkin, Dr. J. Walker, Dr. X. Zhu</p> <p>TBCC Dr. N. Alimohamed, Dr. V. Bramwell, Dr. S. Dowden, Dr. D. Heng, Dr. J. Henning, Dr. V. Krause, Dr. S. Lupichuk, Dr. H. McArthur, Dr. N. Nixon, Dr. A. Pabani, Dr. A. Paterson, Dr. G. Roldan Urgoiti, Dr. D. Ruether, Dr. D. Stewart, Dr. V. Tam, Dr. P. Tang, Dr. R. Tsang, Dr. S. Verma, Dr. M. Webster</p> <p>Grande Prairie Dr. Marie Moreau</p> <p>Lethbridge Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. J. Foley, Dr. S. Raissouni</p> <p>Red Deer Dr. N. Basappa, Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. C. Tarukandirwa, Dr. J. Walker</p> <p>As recommended by the breast tumour program or outlined under group 2 drugs on first page.</p> | Oct/13 | basic |
| ERLOTINIB | 2 | tablets | <p>Lung</p> <ul style="list-style-type: none"> For the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen or for EGFR mutation positive patients who are intolerant to gefitinib/afatinib. Not to be used after progression on gefitinib/afatinib Prescribing limited to written authorization by named physicians: <p>CCI Dr. D. Au, Dr. N. Basappa, Dr. C. Butts, Dr. Q. Chu, Dr. A. Joy, Dr. R. Sangha, Dr. M. Sawyer, Dr. M. Smylie</p> <p>TBCC Dr. G. Bebb, Dr. C. Card, Dr. D. Hao, Dr. V. Krause, Dr. D. Morris, Dr. N. Nixon, Dr. A. Pabani, Dr. D. Ruether, Dr. V. Tam, Dr. R. Tsang</p> <p>Grande Prairie Dr. M. Moreau</p> <p>Lethbridge Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. S. Raissouni</p> <p>Red Deer Dr. N. Basappa, Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. C. Tarukandirwa, Dr. J. Walker</p> <p>As recommended by the lung tumour program or outlined under group 2 drugs on first page.</p> | Aug/06 July/13 Oct/11 Sept/14 | n/a |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|------------------------|-------|-------------------------|---|----------------------------|-------------------------------|
| ERWINIA L-ASPARAGINASE | 1 | injectable | | Feb/10 Jun/14 | advanced |
| ETOPOSIDE | 1 | injectable, capsules | | | IV inf. – basic |
| EVEROLIMUS | 2 | tablets | <p>Renal</p> <ul style="list-style-type: none"> For the treatment of patients with metastatic renal cell carcinoma (mRCC) after failure of initial treatment with any VEGF- receptor TKIs (e.g. sunitinib, sorafenib, pazopanib). Not to be used after progression on Nivolumab, may be considered if intolerant to Nivolumab. Prescribing limited to written authorization by named physicians: <p>CCI Dr. N. Basappa, Dr. M. Kolinsky, Dr. S. North, Dr. P. Venner</p> <p>TBCC Dr. N. Alimohamed, Dr. T. Cheng, Dr. D. Heng, Dr. R. Lee-Ying, Dr. N. Nixon, Dr. A. Pabani, Dr. D. Ruether, Dr. V. Tam</p> <p>Grande Prairie Dr. M. Moreau</p> <p>Lethbridge Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. S. Raissouni</p> <p>Red Deer Dr. N. Basappa, Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. C. Tarukandirwa, Dr. J. Walker</p> <p>As recommended by the genitourinary tumour program or outlined under group 2 drugs on first page.</p> | Feb/11 Mar/14 Apr/17 | n/a |
| | | | <p>pNET</p> <ul style="list-style-type: none"> For the treatment of patients with well or moderately – differentiated neuro-endocrine tumours of pancreatic origins (pNETs) in patients with unresectable, locally advanced or metastatic disease who have not previously been treated with sunitinib (unless intolerant). Prescribing limited to written authorization by named physicians: <p>CCI Dr. N. Basappa, Dr. C. Butts, Dr. N. Chua, Dr. M. Ho, Dr. K. King, Dr. S. Koski, Dr. J. Meza-Junco, Dr. K. Mulder, Dr. J. Price Hiller, Dr. M. Sawyer, Dr. A. Scarfe, Dr. J. Spratlin, Dr. J. Walker, Dr. C. Wong, Dr. X. Zhu</p> <p>TBCC Dr. C. Card, Dr. W. Cheung, Dr. S. Dowden, Dr. R. Lee-Ying, Dr. N. Nixon, Dr. G. Roldan Urgoiti, Dr. D. Ruether, Dr. H. Samawi</p> <p>Grande Prairie Dr. M. Moreau</p> <p>Lethbridge Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. S. Raissouni</p> <p>Red Deer Dr. N. Basappa, Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. C. Tarukandirwa, Dr. J. Walker</p> <p>As recommended by the endocrine or gastrointestinal tumour program.</p> | Mar/13 | |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|--------------|-------|---------------------|---|---|-------------------------------|
| EVEROLIMUS | 2 | tablets | <p>Breast Cancer</p> <ul style="list-style-type: none"> For the treatment of hormone-receptor positive, HER2 negative advanced breast cancer in post menopausal women (ECOG ≤ 2) after recurrence or progression following a non-steroidal aromatase inhibitor (NSAI), If the treating oncologist would consider using exemestane. Prescribing limited to written authorization by named physicians: <p>CCI Dr. D. Au, Dr. S. Basi, Dr. M. Ho, Dr. A. Joy, Dr. K. King, Dr. J. Mackey, Dr. J. Meza-Junco, Dr. J. Price Hiller, Dr. A. Scarfe, Dr. M. Smylie, Dr. K. Tonkin, Dr. J. Walker, Dr. X. Zhu</p> <p>TBCC Dr. N. Alimohamed, Dr. V. Bramwell, Dr. S. Dowden, Dr. D. Heng, Dr. J. Henning, Dr. V. Krause, Dr. S. Lupichuk, Dr. H. McArthur, Dr. N. Nixon, Dr. A. Pabani, Dr. A. Paterson, Dr. G. Roldan Urgoiti, Dr. D. Ruether, Dr. D. Stewart, Dr. V. Tam, Dr. P. Tang, Dr. R. Tsang, Dr. S. Verma, Dr. M. Webster</p> <p>Grande Prairie Dr. M. Moreau</p> <p>Lethbridge Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. J. Foley, Dr. S. Raissouni</p> <p>Red Deer Dr. N. Basappa, Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. C. Tarukandirwa, Dr. J. Walker</p> <p>As recommended by the breast tumour program or outlined under group 2 drugs on first page.</p> | Dec/13 | n/a |
| EXEMESTANE | 1 | oral | | Mar/01 Jan/04 Apr/04 May/06 Mar/13 July/13 | n/a |
| FLUDARABINE | 1 | injectable, tablets | | Mar/96 Apr/09 | IV inf. - basic |
| FLUOROURACIL | 1 | injectable, cream | | | IV push, inf. - basic |
| | 1 | pump | electronic continuous infusion pumps Baxter (elastomeric) pumps. | Jan/02 Jan/02 | advanced basic |
| FLUTAMIDE | 1 | tablets | | May/85 Apr/09 | n/a |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|---------------------------------|-------|-------------|---|------------------|---|
| GEFITINIB | 2 | tablets | <p>Lung</p> <ul style="list-style-type: none"> For the first line treatment of epidermal growth factor receptor (EGFR) sensitizing mutation positive non-small cell lung cancer (NSCLC) Prescribing limited to written authorization by named physicians: <p>CCI Dr. D. Au, Dr. N. Basappa, Dr. C. Butts, Dr. Q. Chu, Dr. A. Joy, Dr. R. Sangha, Dr. M. Sawyer, Dr. M. Smylie</p> <p>TBCC Dr. G. Bebb, Dr. C. Card, Dr. D. Hao, Dr. V. Krause, Dr. D. Morris, Dr. N. Nixon, Dr. A. Pabani, Dr. D. Ruether, Dr. V. Tam, Dr. R. Tsang</p> <p>Grande Prairie Dr. M. Moreau</p> <p>Lethbridge Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. S. Raissouni</p> <p>Red Deer Dr. N. Basappa, Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. C. Tarukandirwa, Dr. J. Walker</p> <p>As recommended by the lung tumour program or outlined under group 2 drugs on first page.</p> | Oct/11 | n/a |
| GEMCITABINE | 1 | injectable | | May/10 Jun/11 | basic IV and intravesical use (bladder instillation) |
| GOSERELIN | 1 | injectable | <p>Prostate Cancer</p> <ul style="list-style-type: none"> Restricted to: <ul style="list-style-type: none"> Stage II (T2a-T2c): Neoadjuvant use pre RT (2 months pre and during RT). Neoadjuvant use pre radical prostatectomy (4 months pre). Stage III (T3a-T4b): Neoadjuvant use pre RT (2 months pre and during RT). Adjuvant use (3 years post RT). Stage IV (N1-N3) (M1-M1c): As monotherapy in medical castration. In total androgen blockade (medical castration and nonsteroidal antiandrogen). Guidelines for LHRH use in the above stated stages include: LHRH agonists are indicated for use in patients at risk of thromboembolic disease, strokes (CVA), myocardial infarction and also for consideration in patients with dyslipidemia, hypertension, diabetes mellitus or where a patient is considered intolerant to cyproterone acetate or megestrol acetate. | Jan/98 | n/a |
| HYDROCORTISONE SODIUM SUCCINATE | 1 | injectable | <ul style="list-style-type: none"> Intrathecal use only. | | IT – basic |
| HYDROXYUREA | 1 | capsules | | | n/a |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|------------|-------|-------------|--|------------------|-------------------------------|
| IBRUTINIB | 2 | oral | <p>Hematology</p> <ul style="list-style-type: none">• Ibrutinib for patients with CLL/SLL who have received at least one prior therapy and are considered inappropriate for treatment or retreatment with a fludarabine based regimen.• Prescribing limited to written authorization by named physicians: <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. S. Takach Lapner, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. M. Wong, Dr. V. Zepeda</p> <p>Grande Prairie Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau Dr. G. Nikoleychuk</p> <p>Lethbridge Dr. S. Benke, Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. J. Foley, Dr. S. Raissouni</p> <p>Red Deer Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. K. Rudolph, Dr. C. Tarukandirwa</p> <p>As recommended by the hematology tumour program or outlined under group 2 drugs on first page</p> | Aug/15 | n/a |
| IDARUBICIN | 1 | injectable | | Jul/98 Apr/09 | |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|------------|-------|-------------|--|---------------|-------------------------------|
| IDELALISIB | 2 | tablet | <p>Hematology</p> <ul style="list-style-type: none"> • Idelalisib in combination with rituximab for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL). Treatment should continue until unacceptable toxicity or disease progression. • Prescribing limited to written authorization by named physicians: <p>CCI</p> <p>Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. S. Takach Lapner, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC</p> <p>Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. M. Wong, Dr. V. Zepeda</p> <p>Grande Prairie</p> <p>Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau, Dr. G. Nikoleychuk</p> <p>Lethbridge</p> <p>Dr. S. Benke, Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat</p> <p>Dr. J. Foley, Dr. S. Raissouni</p> <p>Red Deer</p> <p>Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. K. Rudolph, Dr. C. Tarukandirwa</p> <p>As recommended by the hematology tumour program or outlined under group 2 drugs on first page</p> | Oct/16 | |
| IFOSFAMIDE | 1 | injectable | | | IV inf. – basic |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|----------|-------|-------------|--|------------------|-------------------------------|
| IMATINIB | 2 | tablets | GIST <ul style="list-style-type: none">• For adjuvant treatment of patients who are at high risk of relapse following complete resection of KIT (CD117) positive GIST• For surgically unresectable or metastatic gastrointestinal stromal tumour (GIST).• Prescribing limited to written authorization by named physicians: CCI Dr. N. Basappa, Dr. Q. Chu, Dr. S. McKillop, Dr. K. Mulder, Dr. A.R. Turner TBCC Dr. V. Bramwell, Dr. J. Henning, Dr. H. Karachiwala, Dr. D. Morris, Dr. A. Pabani, Dr. V. Tam Grande Prairie Dr. M. Moreau Medicine Hat Dr. S. Raissouni Lethbridge Dr. M. Brigden, Dr. A. Imbulgoda Red Deer Dr. N. Basappa, Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. C. Tarukandirwa, Dr. J. Walker As recommended by the sarcoma tumour program or outlined under group 2 drugs on first page. | Apr/03 Oct/12 | n/a |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|--------------------|-------|-------------|--|--------------------------------|-------------------------------|
| IMATINIB | 2 | tablets | <p>Hematology</p> <ul style="list-style-type: none"> Philadelphia-chromosome positive leukemia (including disease situations such as first chronic phase chronic myelogenous leukemia (CML), accelerated phase CML, blast crisis phase CML, acute lymphoblastic leukemia, or other leukemia's that have the characteristic t (9;22) trans location detected by cytogenetics, FISH analysis, or PCR-positive for bcr-abl oncogene) Prescribing limited to written authorization by named physicians: <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. S. Takach Lapner, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. M. Wong, Dr. V. Zepeda</p> <p>Grande Prairie Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau, Dr. G. Nikoleychuck</p> <p>Lethbridge Dr. S. Benke, Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. J. Foley, Dr. S. Raissouni</p> <p>Red Deer Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. K. Rudolph, Dr. C. Tarukandirwa</p> <p>As recommended by the hematology tumour program or outlined under group 2 drugs on first page.</p> | Apr/03 Oct/03 | n/a |
| INTERFERON alfa 2b | 1 | injectable | | Jul/97 Apr/09 | basic |
| IPILIMUMAB | 2 | injectable | <p>Melanoma</p> <ul style="list-style-type: none"> For the treatment of advanced melanoma (unresectable Stage III or Stage IV melanoma) in patients who have received prior systemic therapy. Not available following other immunotherapy (e.g. pembrolizumab and nivolumab). for the first line treatment of advanced (unresectable or metastatic) melanoma dosed at 3 mg/kg every 3 weeks for 4 doses. Only patients with a documented response maintained for 6 months are eligible for retreatment. Prescribing limited to written authorization by named physicians: <p>CCI Dr. M. Smylie, Dr. J. Walker</p> <p>TBCC Dr. T. Cheng, Dr. J. Monzon</p> <p>As recommended by the cutaneous tumour program or outlined under group 2 drugs on first page</p> | Oct/12 Jul/16 Mar/15 | advanced |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|---|-------|-------------|---|--|-------------------------------|
| IRINOTECAN *Note: Loperamide supplied by industry with this agent's use. | 1 | injectable | | Jan/00 Mar/98 Oct/03 Jul/06 Aug/09 | IV inf. – basic |
| ISOTRETINOIN | 1 | capsules | | Mar/99 Apr/09 | n/a |
| LAPATINIB | 2 | tablets | <p>Breast Cancer – Metastatic/Advanced</p> <ul style="list-style-type: none"> In combination with capecitabine for the treatment of patients with advanced/metastatic breast cancer whose tumours overexpress ErbB2 (HER-2) after prior taxane and trastuzumab exposure. Prescribing limited to written authorization by named physicians: <p>CCI Dr. D. Au, Dr. S. Basi, Dr. M. Ho, Dr. A. Joy, Dr. K. King, Dr. J. Mackey, Dr. J. Meza-Junco, Dr. J. Price Hiller, Dr. A. Scarfe, Dr. M. Smylie, Dr. K. Tonkin, Dr. J. Walker, Dr. X. Zhu</p> <p>TBCC Dr. N. Alimohamed, Dr. V. Bramwell, Dr. S. Dowden, Dr. D. Heng, Dr. J. Henning, Dr. V. Krause, Dr. S. Lupichuk, Dr. H. McArthur, Dr. N. Nixon, Dr. A. Pabani, Dr. A. Paterson, Dr. G. Roldan Urgoiti, Dr. D. Ruether, Dr. D. Stewart, Dr. V. Tam, Dr. P. Tang, Dr. R. Tsang, Dr. S. Verma, Dr. M. Webster</p> <p>Grande Prairie Dr. M. Moreau</p> <p>Lethbridge Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. J. Foley, Dr. S. Raissouni</p> <p>Red Deer Dr. N. Basappa, Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. C. Tarukandirwa, Dr. J. Walker</p> <p>As recommended by the breast tumour program or outlined under group 2 drugs on first page.</p> | Feb/11 Aug/12 | n/a |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|--------------------|-------|---------------------|---|---|-------------------------------|
| LENALIDOMIDE | 2 | capsules | <p>MDS – for the treatment of anemia due to myelodysplastic syndrome with a deletion of 5q cytogenetic abnormality</p> <p>Multiple Myeloma</p> <ul style="list-style-type: none"> • Lenalidomide as an option for first line treatment in patients with multiple myeloma who are not eligible for autologous stem cell transplantation. Treatment should be in combination with dexamethasone for patients with ECOG PS \leq 2 and until disease progression. • Multiple myeloma after at least one prior therapy. Patients cannot have progressed on prior lenalidomide. • Maintenance treatment for patients with newly diagnosed multiple myeloma following autologous stem cell transplantation. Concurrent use with bortezomib maintenance for high risk patients with any of the del17p, t(4:14) or t(14:16) is approved. • Prescribing limited to named physicians WHO ARE REGISTERED IN RevAID PROGRAM WITH A SPECIFIC PRESCRIBER ID NUMBER: <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. A. Daly, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. J.F.T. Thaell, Dr. K. Valentine, Dr. M. Wong, Dr. J. Yau, Dr. V. Zepeda</p> <p>Grande Prairie Dr. G. Campbell, Dr. J. Hattingh, Dr. S. Marcotte, Dr. M.A. Moreau, Dr. G. Nikoleyчук</p> <p>Lethbridge Dr. S. Benke, Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. J. Foley, Dr. S. Raissouni</p> <p>Red Deer Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. K. Rudolph, Dr. C. Tarukandirwa</p> | Aug/09 Oct/16 Oct/09 Sept/14 Jan/16 | n/a |
| LETROZOLE | 1 | tablets | | Oct/98 Jul/02 Apr/03 Feb/06 Oct/07 Mar/13 July/13 | n/a |
| LEUCOVORIN CALCIUM | 1 | injectable, tablets | | Jul/92 Apr/09 | n/a |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|-----------------------------|-------|------------------------|---|------------------|-------------------------------------|
| LEUPROLIDE | 1 | injectable | Prostate Cancer <ul style="list-style-type: none"> Restricted to: <ul style="list-style-type: none"> Stage II (T2a-T2c): Neoadjuvant use pre RT (2 months pre and during RT). Neoadjuvant use pre radical prostatectomy (4 months pre). Stage III (T3a-T4b): Neoadjuvant use pre RT (2 months pre and during RT). Adjuvant use (3 years post RT). Stage IV (N1-N3) (M1-M1c): As monotherapy in medical castration. In total androgen blockade (medical castration and nonsteroidal antiandrogen). Guidelines for LHRH use in the above stated stages include: <ul style="list-style-type: none"> LHRH agonists are indicated for use in patients at risk of thromboembolic disease, strokes (CVA), myocardial infarction and also for consideration in patients with dyslipidemia, hypertension, diabetes mellitus or where a patient is considered intolerant to cyproterone acetate or megestrol acetate. | Jan/98 | n/a |
| | | | Breast Cancer <ul style="list-style-type: none"> Adjuvant ovarian suppression and endocrine therapy for 5 years in early stage ER+ pre-menopausal breast cancer. Dosing options include 7.5 mg sc monthly and 22.5 mg sc q3 monthly. As treatment in pre- and peri-menopausal patients with metastatic breast cancer. Dosing options include 7.5 mg sc monthly or 22.5 mg sc q3 monthly. | Dec/15 Oct/16 | |
| LOMUSTINE | 1 | capsules | | | n/a |
| MEDROXYPROGESTERONE ACETATE | 1 | tablets | | | n/a |
| MEGESTROL ACETATE | 1 | tablets | | | n/a |
| MELPHALAN | 1 | tablets injectable | | Jul/16 | advanced IV |
| MERCAPTOPYRINE | 1 | tablets | | | n/a |
| MESNA | 1 | injectable | | | n/a |
| METHOTREXATE | 1 | injectable, tablets | | | IM, IV push, IT, IV inf. – basic |
| METHYLPREDNISOLONE | 1 | Injectable | | Jun/14 | basic |
| MITOMYCIN | 1 | injectable | <ul style="list-style-type: none"> 3rd line for bladder cancer indication | | Bladder instillation |
| | | | | | IV push – basic |
| MITOTANE | 1 | oral | | May/08 Sep/10 | n/a |
| MITOXANTRONE | 1 | injectable | | May/85 | IV push, inf. – basic |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|------------------|-------|-------------|--|------------------|-------------------------------|
| (nab)-PACLITAXEL | 2 | injectable | <p>Breast Cancer - Metastatic</p> <ul style="list-style-type: none">• Patients who have had severe acute infusion reactions with paclitaxel or docetaxel, considered by the treating physician to be due to the vehicle of the taxanes (cremophor and polysorbate80); or patients who have experienced severe toxicity* from previous administration of other taxanes. *severe toxicity could be due to the pre-medications for the administration of the taxane or due to the taxane itself.• Prescribing limited to written authorization by named physicians: <p>CCI Dr. D. Au, Dr. S. Basi, Dr. M. Ho, Dr. A. Joy, Dr. K. King, Dr. J. Mackey, Dr. J. Meza-Junco, Dr. J. Price Hiller, Dr. A. Scarfe, Dr. M. Smylie, Dr. K. Tonkin, Dr. J. Walker, Dr. X. Zhu</p> <p>TBCC Dr. N. Alimohamed, Dr. V. Bramwell, Dr. S. Dowden, Dr. D. Heng, Dr. J. Henning, Dr. V. Krause, Dr. S. Lupichuk, Dr. H. McArthur, Dr. N. Nixon, Dr. A. Pabani, Dr. A. Paterson, Dr. G. Roldan Urgoiti, Dr. D. Ruether, Dr. D. Stewart, Dr. V. Tam, Dr. P. Tang, Dr. R. Tsang, Dr. S. Verma, Dr. M. Webster</p> <p>Grande Prairie Dr. M. Moreau</p> <p>Lethbridge Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. J. Foley, Dr. S. Raissouni</p> <p>Red Deer Dr. N. Basappa, Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. C. Tarukandirwa, Dr. J. Walker</p> <p>As recommended by the breast tumour program or outlined under group 2 drugs on first page.</p> | Jan/08 Apr/09 | IV-basic |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|------------------|-------|-------------|---|--------------------------------|-------------------------------|
| (nab)-PACLITAXEL | 2 | injectable | <p>Pancreas</p> <ul style="list-style-type: none">• (nab)-paclitaxel plus gemcitabine as a second line treatment for advanced or metastatic pancreatic cancer after progression on FOLFIRINOX. Funding should be for patients with ECOG performance status 0-2.• (nab)-paclitaxel plus gemcitabine for the first line treatment of patients with locally advanced unresectable or metastatic adenocarcinoma of the pancreas or patients unable to tolerate FOLFIRINOX.• Prescribing limited to written authorization by named physicians <p>CCI Dr. N. Basappa, Dr. C. Butts, Dr. N. Chua, Dr. A.L.A. Fields, Dr. A. Fontaine, Dr. M. Ho, Dr. K. King, Dr. S. Koski, Dr. K. Mulder, Dr. J. Price Hiller, Dr. M. Sawyer, Dr. A. Scarfe, Dr. J. Spratlin, Dr. J. Walker, Dr. C. Wong, Dr. X. Zhu</p> <p>TBCC Dr. V. Bramwell, Dr. W. Cheung, Dr. S. Dowden, Dr. D. Heng, Dr. J. Henning, Dr. V. Krause, Dr. R. Lee-Ying, Dr. S. Lupichuk, Dr. J. Monzon, Dr. N. Nixon, Dr. A. Paterson, Dr. G. Roldan Urgoiti, Dr. D. Ruether, Dr. H. Samawi, Dr. D. Stewart, Dr. V. Tam, Dr. P. Tang, Dr. R. Tsang, Dr. M. Webster</p> <p>Grande Prairie Dr. M. Moreau</p> <p>Lethbridge Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. S. Raissouni</p> <p>Red Deer Dr. N. Basappa, Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. C. Tarukandirwa, Dr. J. Walker</p> <p>As recommended by the gastrointestinal tumour program or outlined under group 2 drugs on first page.</p> | Jan/16 Mar/15 Jan/16 | IV-basic |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|------------|-------|-------------|---|------------------|-------------------------------|
| NILOTINIB | 2 | capsule | <p>Hematology</p> <ul style="list-style-type: none"> • As first line treatment of Philadelphia Chromosome Positive CML in Chronic Phase (CML-CP) • as second line alternative for Imatinib resistant or intolerant, or Dasatinib intolerant CML patients. • Prescribing limited to written authorization by named physicians: <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. S. Takach Lapner, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. M. Wong, Dr. V. Zepeda</p> <p>Grande Prairie Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau, Dr. G. Nikoleychuk</p> <p>Lethbridge Dr. S. Benke, Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. J. Foley, Dr. S. Raissouni</p> <p>Red Deer Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. K. Rudolph, Dr. C. Tarukandirwa</p> <p>As recommended by the hematology tumour program or outlined under group 2 drugs on first page.</p> | Dec/10 Oct/12 | n/a |
| NILUTAMIDE | 1 | tablets | | Jan/93 Apr/09 | n/a |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|-----------|-------|-------------|---|---------------|-------------------------------|
| NIVOLUMAB | 2 | injectable | Lung Cancer <ul style="list-style-type: none">• Nivolumab for the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) who progressed on or after cytotoxic chemotherapy and have a good performance status.• Prescribing limited to written authorization by named physicians: CCI Dr. D. Au, Dr. N. Basappa, Dr. C. Butts, Dr. Q. Chu, Dr. A. Joy, Dr. R. Sangha, Dr. M. Sawyer, Dr. M. Smylie TBCC Dr. G. Bebb, Dr. C. Card, Dr. D. Hao, Dr. V. Krause, Dr. D. Morris, Dr. N. Nixon, Dr. A. Pabani, Dr. D. Ruether, Dr. V. Tam, Dr. R. Tsang Grande Prairie Dr. M. Moreau Lethbridge Dr. M. Brigden, Dr. A. Imbulgoda Medicine Hat Dr. S. Raissouni Red Deer Dr. N. Basappa, Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. C. Tarukandirwa, Dr. J. Walker As recommended by the lung tumour program or outlined under group 2 drugs on first page | Apr/17 | advanced |
| | | | Renal <ul style="list-style-type: none">• Nivolumab for the treatment of patients with advanced or metastatic renal cell carcinoma with disease progression after at least one prior anti-angiogenic systemic treatment and who have good performance status. Treatment should continue until disease progression or unacceptable toxicity. It may be used if intolerant to everolimus or axitinib but not to be used after progression on everolimus or axitinib (time limited option to use if these agents were started prior to the nivolumab listing date).• Prescribing limited to written authorization by named physicians: CCI Dr. N. Basappa, Dr. M. Kolinsky, Dr. S. North, Dr. P. Venner TBCC Dr. N. Alimohamed, Dr. T. Cheng, Dr. D. Heng, Dr. R. Lee-Ying, Dr. N. Nixon, Dr. A. Pabani, Dr. D. Ruether, Dr. V. Tam Grande Prairie Dr. M. Moreau Lethbridge Dr. M. Brigden, Dr. A. Imbulgoda Medicine Hat Dr. S. Raissouni Red Deer Dr. N. Basappa, Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. C. Tarukandirwa, Dr. J. Walker As recommended by the genitourinary tumour program or outlined under group 2 drugs on first page. | Apr/17 | advanced |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|--------------|-------|-------------|--|------------------|--------------------------------------|
| NIVOLUMAB | 2 | injectable | <p>Melanoma</p> <ul style="list-style-type: none"> • Nivolumab for the treatment of patients with unresectable or metastatic BRAF wild-type melanoma who are previously untreated, with good performance status and who have stable brain metastases (if present). Treatment should continue until unacceptable toxicity or disease progression. Not to be used for the treatment of patients with BRAF V600 mutations positive unresectable or metastatic melanoma. Not to be used for the treatment of patients who have previously received treatment with ipilimumab or pembrolizumab. • Prescribing limited to written authorization by named physicians: <p>CCI Dr. M. Smylie, Dr. J. Walker</p> <p>TBCC Dr. T. Cheng, Dr. J. Monzon</p> <p>As recommended by the cutaneous tumour program or outlined under group 2 drugs on first page</p> | Apr/17 | advanced |
| OBINUTUZUMAB | 2 | injectable | <p>Hematology</p> <ul style="list-style-type: none"> • Obinutuzumab in combination with chlorambucil in patients previously untreated CLL and adequate renal function for whom fludarabine based treatment is considered inappropriate. • Prescribing limited to written authorization by named physicians: <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. S. Takach Lapner, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. M. Wong, Dr. V. Zepeda</p> <p>Grande Prairie Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau, Dr. G. Nikoleychuk</p> <p>Lethbridge Dr. S. Benke, Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. J. Foley, Dr. S. Raissouni</p> <p>Red Deer Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. K. Rudolph, Dr. C. Tarukandirwa</p> <p>As recommended by the hematology tumour program or outlined under group 2 drugs on first page</p> | Aug/15 | IV-advanced |
| OXALIPLATIN | 1 | injectable | | Jul/16 | IV-basic |
| PACLITAXEL | 1 | injectable | | Dec/98 Apr/09 | IV, Intraperitoneal – advanced |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|---------------|-------|-------------|--|------------------|-------------------------------|
| PANITUMUMAB | 1 | injectable | | Oct/09 Jun/14 | basic |
| PAZOPANIB | 2 | oral | <p>Renal</p> <ul style="list-style-type: none"> As an option in the first line treatment of advanced or metastatic clear cell renal cell carcinoma for patients with good performance status or if patients are unable to tolerate ongoing sunitinib. Not to be used after progression on sunitinib. Prescribing limited to written authorization by named physicians: <p>CCI Dr. N. Basappa, Dr. M. Kolinsky, Dr. S. North, Dr. P. Venner</p> <p>TBCC Dr. N. Alimohamed, Dr. T. Cheng, Dr. D. Heng, Dr. R. Lee-Ying, Dr. N. Nixon, Dr. A. Pabani, Dr. D. Ruether, Dr. V. Tam</p> <p>Grande Prairie Dr. M. Moreau</p> <p>Lethbridge Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. S. Raissouni</p> <p>Red Deer Dr. N. Basappa, Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. C. Tarukandirwa, Dr. J. Walker</p> <p>As recommended by the genitourinary tumour program or outlined under group 2 drugs on first page.</p> | Mar/14 Feb/12 | |
| PEMBROLIZUMAB | 2 | injectable | <p>Melanoma</p> <ul style="list-style-type: none"> Pembrolizumab in patients with unresectable or metastatic melanoma (Stage III or IV) who are naïve to ipilimumab or in patients who have failed ipilimumab (time limited to if started on ipilimumab prior to Pembrolizumab listing date) and if BRAF mutation positive, have failed BRAF mutation targeted therapies. Treatment should be in patients with an ECOG 0-1, who have stable brain metastases (if present), using 2 mg/kg dose every 3 weeks for maximum of 24 months or until disease progression, whichever occurs first. Not to be used in patients who have received Nivolumab. Prescribing limited to written authorization by named physicians: <p>CCI Dr. M. Smylie, Dr. J. Walker</p> <p>TBCC Dr. T. Cheng, Dr. J. Monzon</p> <ul style="list-style-type: none"> As recommended by the cutaneous tumour program or outlined under group 2 drugs on first page | Jul/16 Apr/17 | advanced |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|------------|-------|-------------|--|--|-------------------------------|
| PEMETREXED | 2 | injectable | <p><u>Lung and Gastrointestinal</u></p> <ul style="list-style-type: none"> • Pemetrexed (in combination with cisplatin) for use in patients with malignant mesothelioma • Pemetrexed first line with Platinum followed by maintenance pemetrexed for the treatment of advanced non-small cell lung cancer with non-squamous histology. • Maintenance pemetrexed for the treatment of patients with advanced non-small cell lung cancer (NSCLC) of non-squamous histology following four cycles of palliative platinum-doublet chemotherapy • For second line treatment of patients with non-small cell lung cancer (may be used as third line systemic therapy if prior treatment with an EGFR TKI or ALK inhibitor). Not to be used following Nivolumab progression. • Prescribing limited to written authorization by named physicians: <p>CCI Dr. D. Au, Dr. N. Basappa, Dr. C. Butts, Dr. Q. Chu, Dr. N. Chua, Dr. A.L.A. Fields, Dr. A. Fontaine, Dr. M. Ho, Dr. A. Joy, Dr. K. King, Dr. S. Koski, Dr. K. Mulder, Dr. J. Price Hiller, Dr. R. Sangha, Dr. M. Sawyer, Dr. A. Scarfe, Dr. M. Smylie, Dr. J. Spratlin, Dr. J. Walker, Dr. C. Wong, Dr. X. Zhu</p> <p>TBCC Dr. G. Bebb, Dr. V. Bramwell, Dr. C. Card, Dr. W. Cheung, Dr. S. Dowden, Dr. D. Hao, Dr. D. Heng, Dr. J. Henning, Dr. V. Krause, Dr. R. Lee-Ying, Dr. S. Lupichuk, Dr. J. Monzon, Dr. D. Morris, Dr. N. Nixon, Dr. A. Pabani, Dr. A. Paterson, Dr. G. Roldan Urgoiti, Dr. D. Ruether, Dr. H. Samawi, Dr. D. Stewart, Dr. V. Tam, Dr. P. Tang, Dr. R. Tsang, Dr. M. Webster</p> <p>Grande Prairie Dr. D. Moreau</p> <p>Lethbridge Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. S. Raissouni</p> <p>Red Deer Dr. N. Basappa, Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. C. Tarukandirwa, Dr. J. Walker</p> <p>As recommended by the lung or gastrointestinal tumour group program or outlined under group 2 drugs on first page.</p> | Feb/05 Oct/12 May/14 Jun/14 May/08 May/14 Apr/17 | basic |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|------------|-------|-------------|---|---------------|-------------------------------|
| PERTUZUMAB | 2 | injectable | <p>Breast Cancer</p> <ul style="list-style-type: none">• In combination with trastuzumab and a taxane for the treatment of patients with HER2 positive unresectable locally recurrent or metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease or who have not relapsed within 6 months of receiving trastuzumab in the adjuvant setting• Prescribing limited to written authorization by named physicians: <p>CCI Dr. D. Au, Dr. S. Basi, Dr. M. Ho, Dr. A. Joy, Dr. K. King, Dr. J. Mackey, Dr. J. Meza-Junco, Dr. J. Price Hiller, Dr. A. Scarfe, Dr. M. Smylie, Dr. K. Tonkin, Dr. J. Walker, Dr. X. Zhu</p> <p>TBCC Dr. N. Alimohamed, Dr. V. Bramwell, Dr. S. Dowden, Dr. D. Heng, Dr. J. Henning, Dr. V. Krause, Dr. S. Lupichuk, Dr. H. McArthur, Dr. N. Nixon, Dr. A. Pabani, Dr. A. Paterson, Dr. G. Roldan Urgoiti, Dr. D. Ruether, Dr. D. Stewart, Dr. V. Tam, Dr. P. Tang, Dr. R. Tsang, Dr. S. Verma, Dr. M. Webster</p> <p>Grande Prairie Dr. M. Moreau</p> <p>Lethbridge Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. J. Foley, Dr. S. Raissouni</p> <p>Red Deer Dr. N. Basappa, Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. C. Tarukandirwa, Dr. J. Walker</p> <p>As recommended by the breast tumour program or outlined under group 2 drugs on first page.</p> | Dec/13 | advanced |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|--------------|-------|-------------|---|------------------|-------------------------------|
| POMALIDOMIDE | 2 | capsule | <p>Hematology</p> <ul style="list-style-type: none">• Pomalidomide and dexamethasone (with or without cyclophosphamide) in patients with relapsed and/or refractory multiple myeloma who have previously failed at least two treatments, including Bortezomib and Lenalidomide and demonstrated disease progression on the last treatment. Pomalidomide as an option in rare instances where Bortezomib is a contraindication or when patients are intolerant to it and have failed Lenalidomide. In exceptional circumstances where dexamethasone is contraindicated, prednisone may be used. The steroid component may be withheld altogether if warranted by the risk of toxicity.• Prescribing limited to named physicians WHO ARE REGISTERED IN RevAID PROGRAM WITH A SPECIFIC PRESCRIBER ID NUMBER: <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. M. Wong, Dr. V. Zepeda</p> <p>Grande Prairie Dr. G. Campbell, Dr. J. Hattingh, Dr. S. Marcotte, Dr. M.A. Moreau, Dr. G. Nikoleyчук</p> <p>Lethbridge Dr. S. Benke, Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. J. Foley, Dr. S. Raissouni</p> <p>Red Deer Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. C. Tarukandirwa, Dr. K. Rudolph</p> | Apr/15 Jan/16 | n/a |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|-------------------------------|-------|-------------|--|----------------------------|-------------------------------|
| PONATINIB | 2 | oral | <p>Hematology</p> <ul style="list-style-type: none"> • Ponatinib for the treatment of patients with chronic phase, accelerated phase, or blast phase Chronic Myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ve) ALL) for whom other tyrosine kinase inhibitor (TKI) therapy is not appropriate, including CML or PH+ve ALL that is T315I mutation positive or where there is resistance or intolerance to prior TKI therapy. Funding should be for patients with ECOG performance status 0-2. Treatment should continue until unacceptable toxicity or disease progression. • Prescribing limited to written authorization by named physicians: <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. S. Takach Lapner, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. M. Wong, Dr. V. Zepeda</p> <p>Grande Prairie Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau, Dr. G. Nikoleychuk</p> <p>Lethbridge Dr. S. Benke, Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. J. Foley, Dr. S. Raissouni</p> <p>Red Deer Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. K. Rudolph, Dr. C. Tarukandirwa</p> <p>As recommended by the hematology tumour program or outlined under group 2 drugs on first page. Note: Controlled Distribution Program limited to TBCC and CCI Pharmacy</p> | Oct/16 | |
| PREDNISOLONE SODIUM PHOSPHATE | 1 | liquid | | Nov/96 Apr/09 | n/a |
| PREDNISON | 1 | tablets | | | n/a |
| PROCARBAZINE | 1 | capsules | | Oct/05 Apr/09 | n/a |
| RALTITREXED | 1 | injectable | | Jul/97 Mar/03 Apr/09 | IV inf. – basic |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|-------------|-------|-------------|---|---------------|-------------------------------|
| RAMUCIRUMAB | 2 | injectable | <p>Gastrointestinal</p> <ul style="list-style-type: none"> • Ramucirumab in combination with paclitaxel for the treatment of patients with advanced or metastatic gastric cancer or gastro-esophageal junction adenocarcinoma with ECOG performance status of 0 or 1 and with disease progression following first line chemotherapy. • Prescribing limited to written authorization by named physicians: <p>CCI Dr. N. Basappa, Dr. C. Butts, Dr. N. Chua, Dr. A.L.A. Fields, Dr. A. Fontaine, Dr. M. Ho, Dr. K. King, Dr. S. Koski, Dr. K. Mulder, Dr. J. Price Hiller, Dr. M. Sawyer, Dr. A. Scarfe, Dr. J. Spratlin, Dr. J. Walker, Dr. C. Wong, Dr. X. Zhu</p> <p>TBCC Dr. V. Bramwell, Dr. W. Cheung, Dr. S. Dowden, Dr. D. Heng, Dr. J. Henning, Dr. V. Krause, Dr. R. Lee-Ying, Dr. S. Lupichuk, Dr. J. Monzon, Dr. N. Nixon, Dr. A. Paterson, Dr. G. Roldan Urgoiti, Dr. D. Ruether, Dr. H. Samawi, Dr. D. Stewart, Dr. V. Tam, Dr. P. Tang, Dr. R. Tsang, Dr. M. Webster</p> <p>Grande Prairie Dr. M. Moreau</p> <p>Lethbridge Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. J. Foley, Dr. S. Raissouni</p> <p>Red Deer Dr. N. Basappa, Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. C. Tarukandirwa, Dr. J. Walker</p> <p>As recommended by the gastrointestinal tumour group or outlined under group 2 drugs on first page.</p> | Apr/17 | advanced |
| REGORAFENIB | 2 | Tablets | <p>GIST</p> <ul style="list-style-type: none"> • In the treatment of patients with metastatic and/or unresectable gastrointestinal stromal tumours (GIST) who have had disease progression on or intolerance to imatinib and sunitinib, in patients with ECOG of 0 or 1 • Prescribing limited to written authorization by named physicians: <p>CCI Dr. N. Basappa, Dr. Q. Chu, Dr. K. Mulder, Dr. S. Mckillop, Dr. A.R. Turner</p> <p>TBCC Dr. V. Bramwell, Dr. J. Henning, Dr. H. Karachiwala, Dr. D. Morris, Dr. A. Pabani, Dr. V. Tam</p> <p>Grande Prairie Dr. M. Moreau</p> <p>Medicine Hat Dr. S. Raissouni</p> <p>Lethbridge Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Red Deer Dr. N. Basappa, Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. C. Tarukandirwa, Dr. J. Walker</p> <p>As recommended by the sarcoma tumour program or outlined under group 2 drugs on first page.</p> | Mar/15 | n/a |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|-----------|-------|------------------------|--|--|--|
| RITUXIMAB | 2 | Injectable IV or SC | <p>Hematology</p> <ul style="list-style-type: none"> • Rituximab plus chemotherapy for patients with follicular, mantle cell, and other indolent B-cell lymphomas who have had no prior treatment with Rituximab. • Relapsed or refractory follicular or other indolent B-cell lymphomas. • In combination with chemotherapy for aggressive histology B-cell CD20 positive non-Hodgkin's lymphoma (any age or stage). • For Post Transplant Lymphoproliferative Disorders (PTLD). • Maintenance Rituximab for Follicular Lymphoma patients who are in remissions (CR or PR) following chemotherapy +/- Rituxan induction. • Extended maintenance therapy for 8 doses in patients with indolent CD-20(+) B cell lymphomas who have recently (within 3 months) responded to systemic therapy and have never previously received maintenance Rituximab. • Reinduction chemotherapy (including high dose therapy and ASCT) for patients with CD-20(+) Large B cell lymphomas who are in first relapse after at least a 6 month remission following initial rituximab containing chemotherapy (and who are considered potential candidate for high dose therapy and autologous stem cell transplantation (no serious co-morbidities, no CNS lymphoma). • Maintenance rituximab given every two months for transplant ineligible mantle cell lymphoma patients after induction chemotherapy until progression. • Monotherapy (weekly x 4 doses) as initial treatment for patients with follicular, mantle cell or other indolent B-cell lymphoma who have contraindications to, or who cannot tolerate chemotherapy. | <p>Oct/16</p> <p>Apr/17</p> <p>Sept/04</p> <p>Apr/17</p> <p>Jan/00</p> <p>Mar/01</p> <p>May/04</p> <p>Apr/12</p> <p>Apr/03</p> <p>Mar/07</p> <p>May/08</p> <p>May/10</p> <p>Apr/12</p> | <p>IV – advanced</p> <p>SC – basic</p> |
| | | Injectable IV only | <ul style="list-style-type: none"> • Rituximab for 8 doses in combination with Idelalisib for the treatment of patients with relapsed chronic Lymphocytic Leukemia (CLL). • Rituximab in combination with chemotherapy as first-line treatment of chronic lymphocytic leukemia. • Monotherapy (after corticosteroid failure) for autoimmune cytopenias due to CLL or other indolent B-Cell lymphomas. • Prescribing limited to written authorization by named physicians: (See following page) | <p>Jan/12</p> <p>July/13</p> <p>Apr/17</p> <p>July/13</p> | |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|-----------|-------|-------------|--|---------------|-------------------------------|
| RITUXIMAB | 2 | injectable | <p>Hematology (Criteria previous page)</p> <ul style="list-style-type: none">• Prescribing limited to written authorization by named physicians: <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. S. Takach Lapner, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. M. Wong, Dr. V. Zepeda</p> <p>Grande Prairie Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau, Dr. G. Nikoleychuk</p> <p>Lethbridge Dr. S. Benke, Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. J. Foley, Dr. S. Raissouni</p> <p>Red Deer Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. K. Rudolph, Dr. C. Tarukandirwa</p> <p>As recommended by the hematology tumour program or outlined under group 2 drugs on first page.</p> | | |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|------------|-------|-------------|---|---------------|-------------------------------|
| ROMIDEPSIN | 2 | injectable | <p>Hematology</p> <ul style="list-style-type: none">For patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) who are not eligible for transplant, have received at least one prior systemic therapy and have an ECOG performance status of 0 to 2.Prescribing limited to written authorization by named physicians: <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. S. Takach Lapner, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. M. Wong, Dr. V. Zepeda</p> <p>Grande Prairie Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau, Dr. G. Nikoleychuk</p> <p>Lethbridge Dr. S. Benke, Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. J. Foley, Dr. S. Raissouni</p> <p>Red Deer Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. K. Rudolph, Dr. C. Tarukandirwa</p> <p>As recommended by the hematology tumour group program or outlined under group 2 drugs on first page.</p> | Dec/15 | advanced |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|-------------|-------|-------------|---|---------------|-------------------------------|
| RUXOLITINIB | 2 | oral | <p>Hematology</p> <ul style="list-style-type: none">For patients with intermediate to high risk symptomatic Myelofibrosis (MF) as assessed using the Dynamic International Prognostic Scoring System (DIPSS) Plus or patients with symptomatic splenomegaly. Patients who have ECOG performance status ≤ 3 and be either previously untreated or refractory to other treatment.Prescribing limited to written authorization by named physicians: <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. S. Takach Lapner, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. M. Wong, Dr. V. Zepeda</p> <p>Grande Prairie Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau, Dr. G. Nikoleychuk</p> <p>Lethbridge Dr. S. Benke, Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. J. Foley, Dr. S. Raissouni</p> <p>Red Deer Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. K. Rudolph, Dr. C. Tarukandirwa</p> <p>As recommended by the hematology tumour program or outlined under group 2 drugs on first page.</p> | Oct/13 | n/a |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|--------------|-------|-------------|--|---------------|-------------------------------|
| SORAFENIB | 2 | tablets | <p>Advanced Hepatocellular Carcinoma</p> <ul style="list-style-type: none"> • For patients with Child Pugh Class A advanced hepatocellular carcinoma, • Have ECOG status 0, 1, or 2; and • Patients who have either progressed on trans-arterial chemoembolization (TACE) or are not suitable for the TACE procedure • Prescribing limited to written authorization by named physicians: <p>CCI Dr. N. Basappa, Dr. C. Butts, Dr. N. Chua, Dr. A.L.A. Fields, Dr. A. Fontaine, Dr. M. Ho, Dr. K. King, Dr. S. Koski, Dr. K. Mulder, Dr. J. Price Hiller, Dr. M. Sawyer, Dr. A. Scarfe, Dr. J. Spratlin, Dr. J. Walker, Dr. C. Wong, Dr. X. Zhu</p> <p>TBCC Dr. V. Bramwell, Dr. W. Cheung, Dr. S. Dowden, Dr. D. Heng, Dr. J. Henning, Dr. V. Krause, Dr. R. Lee-Ying, Dr. S. Lupichuk, Dr. J. Monzon, Dr. N. Nixon, Dr. A. Paterson, Dr. G. Roldan Urgoiti, Dr. D. Ruether, Dr. H. Samawi, Dr. D. Stewart, Dr. V. Tam, Dr. P. Tang, Dr. R. Tsang, Dr. M. Webster</p> <p>Grande Prairie Dr. M. Moreau</p> <p>Lethbridge Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. S. Raissouni</p> <p>Red Deer Dr. N. Basappa, Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. C. Tarukandirwa, Dr. J. Walker</p> <p>As recommended by the gastrointestinal tumour program or outlined under group 2 drugs on first page</p> | Apr/09 | n/a |
| | | | <p>Renal</p> <ul style="list-style-type: none"> • as second line treatment (after failure of cytokine therapy) for advanced/Metastatic renal cell carcinoma • Prescribing limited to written authorization by named physicians: <p>CCI Dr. N. Basappa, Dr. M. Kolinsky, Dr. S. North, Dr. P. Venner</p> <p>TBCC Dr. N. Alimohamed, Dr. T. Cheng, Dr. D. Heng, Dr. R. Lee-Ying, Dr. N. Nixon, Dr. A. Pabani, Dr. D. Ruether, Dr. V. Tam</p> <p>Grande Prairie Dr. M. Moreau</p> <p>Lethbridge Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. S. Raissouni</p> <p>Red Deer Dr. N. Basappa, Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. C. Tarukandirwa, Dr. J. Walker</p> <p>As recommended by the genitourinary tumour program or outlined under group 2 drugs on first page.</p> | Oct/09 | |
| STREPTOZOCIN | 1 | injectable | | May/85 | IV inf. – basic |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|-----------|-------|-------------|---|------------------|-------------------------------|
| SUNITINIB | 2 | capsule | <p>GIST</p> <ul style="list-style-type: none"> Metastatic or unresectable Gastrointestinal Stromal Tumour (GIST) after disease progression on or after intolerance to imatinib Prescribing limited to written authorization by named physicians: <p>CCI Dr. Q. Chu, Dr. S. McKillop, Dr. K. Mulder, Dr. A.R. Turner</p> <p>TBCC Dr. V. Bramwell, Dr. J. Henning, Dr. H. Karachiwala, Dr. D. Morris, Dr. V. Tam</p> <p>Grande Prairie Dr. M. Moreau</p> <p>Lethbridge Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. S. Raissouni</p> <p>Red Deer Dr. N. Basappa, Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. C. Tarukandirwa, Dr. J. Walker</p> <p>As recommended by the sarcoma tumour program or outlined under group 2 drugs on first page.</p> | Oct/07 | n/a |
| | | | <p>Renal</p> <ul style="list-style-type: none"> First line in advanced/metastatic renal cell carcinoma or second line after interferon failure/intolerance or if patients unable to tolerate ongoing first line pazopanib. Not to be used after progression on pazopanib. Prescribing limited to written authorization by named physicians: <p>CCI Dr. N. Basappa, Dr. M. Kolinsky, Dr. S. North, Dr. P. Venner</p> <p>TBCC Dr. N. Alimohamed, Dr. T. Cheng, Dr. D. Heng, Dr. R. Lee-Ying, Dr. N. Nixon, Dr. A. Pabani, Dr. D. Ruether, Dr. V. Tam</p> <p>Grande Prairie Dr. M. Moreau</p> <p>Lethbridge Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. S. Raissouni</p> <p>Red Deer Dr. N. Basappa, Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. C. Tarukandirwa, Dr. J. Walker</p> <p>As recommended by the genitourinary tumour program or outlined under group 2 drugs on first page.</p> | Feb/08 Mar/14 | n/a |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|--------------|-------|-------------|---|------------------|-------------------------------|
| SUNITINIB | 2 | capsule | <p>pNET</p> <ul style="list-style-type: none"> For the treatment of patients with unresectable locally advanced or metastatic well-differentiated pancreatic endocrine tumours (pancreatic NET) whose disease is progressive and who have not previously been treated with everolimus (unless intolerant). Prescribing limited to written authorization by named physicians: <p>CCI Dr. N. Basappa, Dr. C Butts, Dr. N. Chua, Dr. M. Ho, Dr. K. King, Dr. S. Koski, Dr. J. Meza-Junco, Dr. K. Mulder, Dr. J. Price Hiller, Dr. M. Sawyer, Dr. A. Scarfe, Dr. J. Spratlin, Dr. C. Wong, Dr. X. Zhu</p> <p>TBCC Dr. C. Card, Dr. W. Cheung, Dr. S. Dowden, Dr. R. Lee-Ying, Dr. N. Nixon, Dr. G. Roldan Urgoiti, Dr. D. Ruether, Dr. H. Samawi</p> <p>Grande Prairie Dr. M. Moreau</p> <p>Lethbridge Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. S. Raissouni</p> <p>Red Deer Dr. N. Basappa, Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. C. Tarukandirwa, Dr. J. Walker</p> <p>As recommended by the endocrine or gastrointestinal tumour program.</p> | Mar/13 | n/a |
| TAMOXIFEN | 1 | tablets | | Jul/92 | n/a |
| TEMOZOLOMIDE | 1 | | | Jul/16 | n/a |
| TEMSIROLIMUS | 1 | injectable | | Nov/10 Jun/14 | IV-basic |
| THIOGUANINE | 1 | tablets | | | n/a |
| TOPOTECAN | 1 | injectable | | Jul/97 Apr/09 | IV inf. – basic |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|-------------|-------|-------------|---|--|--|
| TRAMETINIB | 2 | oral | <p>Melanoma</p> <ul style="list-style-type: none"> Dabrafenib and/or trametinib for patients with BRAF V600 mutation positive, unresectable or metastatic melanoma in the first line setting and who have an ECOG performance status of 0 or 1. Treatment is until disease progression. If brain metastases are present, patient should be asymptomatic or have stable symptoms. Not to be used after progression on single-agent BRAF inhibitor or MEK inhibitor. Prescribing limited to written authorization by named physicians: <p>CCI Dr. M. Smylie, Dr. J. Walker</p> <p>TBCC Dr. T. Cheng, Dr. J. Monzon</p> <p>As recommended by the cutaneous tumour program or outlined under group 2 drugs on first page</p> | Oct/16 | n/a |
| TRASTUZUMAB | 2 | injectable | <p>Metastatic Breast</p> <ul style="list-style-type: none"> Restricted to the treatment of metastatic breast cancer, HER 2 protein overexpression (+3) by IHC or HER2 amplification by FISH. For the 2nd line treatment of HER2 positive metastatic breast cancer when used in combination with chemotherapy after previous exposure to trastuzumab-base treatments in the metastatic setting. Prescribing limited to written authorization by named physicians: <p>CCI Dr. D. Au, Dr. S. Basi, Dr. M. Ho, Dr. A. Joy, Dr. K. King, Dr. J. Mackey, Dr. J. Meza-Junco, Dr. J. Price Hiller, Dr. A. Scarfe, Dr. M. Smylie, Dr. K. Tonkin, Dr. J. Walker, Dr. X. Zhu</p> <p>TBCC Dr. N. Alimohamed, Dr. V. Bramwell, Dr. S. Dowden, Dr. D. Heng, Dr. J. Henning, Dr. V. Krause, Dr. S. Lupichuk, Dr. H. McArthur, Dr. N. Nixon, Dr. A. Pabani, Dr. A. Paterson, Dr. G. Roldan Urgoiti, Dr. D. Ruether, Dr. D. Stewart, Dr. V. Tam, Dr. P. Tang, Dr. R. Tsang, Dr. S. Verma, Dr. M. Webster</p> <p>Grande Prairie Dr. M. Moreau</p> <p>Lethbridge Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. J. Foley, Dr. S. Raissouni</p> <p>Red Deer Dr. N. Basappa, Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. C. Tarukandirwa, Dr. J. Walker</p> <ul style="list-style-type: none"> As recommended by the breast tumour program or outlined under group 2 drugs on first page. | Jan/00 Feb/02 Nov/03 Feb/12 | IV load dose - Advanced IV maintenance (2mg/kg weekly or 6mg/kg every 3 weeks) – basic |

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|-------------|-------|-------------|--|---------------|--|
| TRASTUZUMAB | 2 | injectable | <p>Breast Cancer</p> <ul style="list-style-type: none"> • Adjuvant/Neoadjuvant treatment of Stage 1-3, HER-2 positive breast cancer for use with or following chemotherapy • Prescribing limited to written authorization by named physicians: <p>CCI Dr. D. Au, Dr. S. Basi, Dr. M. Ho, Dr. A. Joy, Dr. K. King, Dr. J. Mackey, Dr. J. Meza-Junco, Dr. J. Price Hiller, Dr. A. Scarfe, Dr. M. Smylie, Dr. K. Tonkin, Dr. J. Walker, Dr. X. Zhu</p> <p>TBCC Dr. N. Alimohamed, Dr. V. Bramwell, Dr. S. Dowden, Dr. D. Heng, Dr. J. Henning, Dr. V. Krause, Dr. S. Lupichuk, Dr. H. McArthur, Dr. N. Nixon, Dr. A. Pabani, Dr. A. Paterson, Dr. G. Roldan Urgoiti, Dr. D. Ruether, Dr. D. Stewart, Dr. V. Tam, Dr. P. Tang, Dr. R. Tsang, Dr. S. Verma, Dr. M. Webster</p> <p>Grande Prairie Dr. M. Moreau</p> <p>Lethbridge Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. J. Foley, Dr. S. Raissouni</p> <p>Red Deer Dr. N. Basappa, Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. C. Tarukandirwa, Dr. J. Walker</p> <p>As recommended by the breast tumour program or outlined under group 2 drugs on first page.</p> | Aug/06 | basic |
| | | | <p>Metastatic Gastroesophageal Cancer</p> <ul style="list-style-type: none"> • Trastuzumab in conjunction with Cisplatin and either 5-Fluorouracil or Capecitabine as palliative treatment for advanced adenocarcinoma of the stomach and gastroesophageal junction that demonstrates HER2 over-expression (immunohistochemistry score 3+ or 2+ with in situ hybridization positivity). • Prescribing limited to written authorization by named physicians: <p>CCI Dr. N. Basappa, Dr. C. Butts, Dr. N. Chua, Dr. A.L.A. Fields, Dr. A. Fontaine, Dr. M. Ho, Dr. K. King, Dr. S. Koski, Dr. K. Mulder, Dr. J. Price Hiller, Dr. M. Sawyer, Dr. A. Scarfe, Dr. J. Spratlin, Dr. J. Walker, Dr. C. Wong, Dr. X. Zhu</p> <p>TBCC Dr. V. Bramwell, Dr. W. Cheung, Dr. S. Dowden, Dr. D. Heng, Dr. J. Henning, Dr. V. Krause, Dr. R. Lee-Ying, Dr. S. Lupichuk, Dr. J. Monzon, Dr. N. Nixon, Dr. A. Paterson, Dr. G. Roldan Urgoiti, Dr. D. Ruether, Dr. H. Samawi, Dr. D. Stewart, Dr. V. Tam, Dr. P. Tang, Dr. R. Tsang, Dr. M. Webster</p> <p>Grande Prairie Dr. M. Moreau</p> <p>Lethbridge Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. J. Foley, Dr. S. Raissouni</p> <p>Red Deer Dr. N. Basappa, Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. C. Tarukandirwa, Dr. J. Walker</p> <p>As recommended by the gastrointestinal tumour group or outlined under group 2 drugs on first page.</p> | Aug/12 | IV load dose - advanced IV maintenance (6mg/kg every 3 weeks) – basic |

Ministerial Approval: April 3, 2017

Revised: May 12, 2017

Revised: June 1, 2017

Revised: July 24, 2017

Revised: September 19, 2017

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|---------------------------------|-------|-------------|---|----------------------------|-------------------------------|
| TRASTUZUMAB EMTANSINE (KADCYLA) | 2 | injectable | <p>Breast Cancer</p> <ul style="list-style-type: none"> In the second line setting for patients with HER2-positive unresectable locally advanced or metastatic breast cancer. Patients should be ECOG performance status of 0 or 1. Patients must have received prior treatment with Trastuzumab plus chemotherapy (+/- pertuzumab) in the metastatic setting or have disease recurrence during or within 6 months of completing adjuvant therapy with Trastuzumab plus chemotherapy (+/- pertuzumab). Prescribing limited to written authorization by named physicians: <p>CCI Dr. D. Au, Dr. S. Basi, Dr. M. Ho, Dr. A. Joy, Dr. K. King, Dr. J. Mackey, Dr. J. Meza-Junco, Dr. J. Price Hiller, Dr. A. Scarfe, Dr. M. Smylie, Dr. K. Tonkin, Dr. J. Walker, Dr. X. Zhu</p> <p>TBCC Dr. N. Alimohamed, Dr. V. Bramwell, Dr. S. Dowden, Dr. D. Heng, Dr. J. Henning, Dr. V. Krause, Dr. S. Lupichuk, Dr. H. McArthur, Dr. N. Nixon, Dr. A. Pabani, Dr. A. Paterson, Dr. G. Roldan Urgoiti, Dr. D. Ruether, Dr. D. Stewart, Dr. V. Tam, Dr. P. Tang, Dr. R. Tsang, Dr. S. Verma, Dr. M. Webster</p> <p>Grande Prairie Dr. M. Moreau</p> <p>Lethbridge Dr. M. Brigden, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. J. Foley, Dr. S. Raissouni</p> <p>Red Deer Dr. N. Basappa, Dr. F. El-Gehani, Dr. H. Karachiwala, Dr. C. Tarukandirwa, Dr. J. Walker</p> <p>As recommended by the breast tumour program or outlined under group 2 drugs on first page.</p> | Jun/14 | basic |
| TRETINOIN | 1 | capsules | | May/95 Apr/09 | n/a |
| VEMURAFENIB | 2 | oral | <p>Melanoma</p> <ul style="list-style-type: none"> Treatment of BRAF V600 mutation – positive unresectable or metastatic melanoma or if patient is intolerant to dabrafenib and/or trametinib. Not to be used after progression on dabrafenib and/or trametinib. Prescribing limited to written authorization by named physicians: <p>CCI Dr. M. Smylie, Dr. J. Walker</p> <p>TBCC Dr. T. Cheng, Dr. J. Monzon</p> <p>As recommended by the cutaneous tumour program or outlined under group 2 drugs on first page</p> | Oct/12 Mar/15 Oct/16 | n/a |
| VINBLASTINE | 1 | injectable | | | IV push - basic |
| VINCRIStINE | 1 | injectable | | | IV push – basic |
| VINORELBINE | 1 | injectable | | Jul/95 Apr/09 | IV inf. - basic |

| Drug | Group | Dosage Form | Criteria | Approval Date | Administration Classification |
|------------|-------|-------------|---|---------------|-------------------------------|
| VISMODEGIB | 2 | Oral | <p>Cutaneous</p> <ul style="list-style-type: none"> • For the treatment of metastatic basal cell carcinoma (BCC) or locally advanced BCC (including patients with basal cell nevus syndrome, i.e., Gorlin syndrome) in patients who meet the following criteria: <ul style="list-style-type: none"> - patients must have measurable metastatic disease or locally advanced disease; AND - patients' disease must be considered inoperable or inappropriate for surgery; AND - patients' disease must be considered inappropriate for radiotherapy, AND - patient is 18 year of age or older, AND - patient has an EGOG≤2 <p>Dose is 150 mg orally once daily taken until disease progression or unacceptable toxicity. Physicians must provide rationale for why surgery AND radiation cannot be considered</p> <ul style="list-style-type: none"> - must include a surgical consult note that provides a preoperative/surgical evaluation why surgery is not appropriate for the patient; AND - a consult note as to why radiation therapy is not appropriate for the patient: AND - both of the above evaluations must come from a physician who is not the ordering physician, AND - the chart must include confirmation that the patient has been discussed at a multi-disciplinary cancer conference (MCC) or equivalent. <p>Note: considered inoperable or inappropriate for surgery for at least ONE of the following reasons:</p> <ul style="list-style-type: none"> - technically not possible to perform surgery due to size/location/invasiveness of BCC (either lesion too large or can be several small lesions making surgery not feasible) OR - recurrence of BCC after two or more surgical procedures and curative resection unlikely; OR - substantial deformity and/or morbidity anticipated from surgery <p>Note: considered inappropriate for radiation for at least ONE of the following reasons:</p> <ul style="list-style-type: none"> - contraindication to radiation (e.g. Gorlin syndrome) OR - prior radiation lesion: OR - suboptimal outcomes expected due to size/location/invasiveness of BCC <p>Note: patients preference for oral therapy will not be considered</p> <ul style="list-style-type: none"> • Prescribing limited to named physicians WHO ARE REGISTERED IN EPPP PROGRAM WITH A SPECIFIC PRESCRIBER ID NUMBER: <p>CCI Dr. M. Smylie, Dr. J. Walker</p> <p>TBCC Dr. T. Cheng, Dr. J. Monzon</p> <p>As recommended by the cutaneous tumour program or outlined under group 2 drugs on first page</p> | Jun/14 | basic |